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SUMMARY 
Glioblastoma Multiforme (GBM) is the most common malignant brain tumor in 
adults, displaying fast growth, vascular proliferation, diffuse infiltrative nature into the 
brain parenchyma and necrosis areas. Despite optimal multimodal therapeutical 
treatment including surgical resection followed by radiotherapy and chemotherapy, the 
prognosis of patients remains still dismal, with a median survival of 14 months. One 
hypothesis seems to be related to the existence in the brain of the Cancer Stem Cells 
(CSCs). These cells are so-called Glioma Stem Cells (GSCs) and are described as a sub 
population of undifferentiated tumor-cells with stem-like properties, self-renewal, 
multi-lineage differentiation ability, maintained proliferation and highly tumorigenic 
potential in immune-deficient mice. GSCs seem to be play a key role in GBM initiation 
and progression, contributing to chemotherapy and radiotherapy resistance and tumor 
recurrence. 
Therefore, there is an urgent need to develop novel therapeutic approaches, to 
selectively target GSCs.  
In this study, we focus on two different therapeutical approaches:  
- the use of Mesenchymal Stem Cells (MSCs) as delivery vehicles for brain tumor 
therapy, exploiting their inherent tumor-tropism probably related to the effect of 
cytokines and chemokines, secreted by infiltrated tissues. 
- Virotherapy, employing the R3616 as neuroattenuated Herpes Simplex Virus 
type1. R3616 is a HSV1 mutant deleted for both copies of the gene γ34.5, 
important for viral replication and neurovirulence. The effect of these deletions 
inhibits autophagy, blocks virus-induced host protein shutoff, and attenuate virus 
replication in GSCs, minimizing neurotoxicity.  
GSCs employed for this study have been isolated from GBM specimens obtained during 
surgical procedures of tumor removal and cultured in adhesion under normoxic and 
hypoxic conditions or in suspension as neurospheres under normoxic conditions. 
Neuropheres were phenotypically characterized for some of stemness markers, such as 
CD133, Nestin, Sox2 and CD44. 
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In order to choose the best cell candidate for cell delivery experiments, we investigated 
between hMSCs isolated from human bone marrow of healthy donors (BM-MSCs) and 
glioma patients adipose tissue (AT-MSCs) obtained during GBM surgical resection. 
hMSCs from both sources were phenotypically characterized and cultured under 
hypoxic and normoxic conditions in order to mimic the peculiar and heterogeneous 
GBM microenvironment towards cells would be further delivered. The BM-MSCs 
retained: a.) faster growth, b.) a greater in vitro multilineage differentiative potential and 
c.) increased migratory ability than AT-MSCs, especially in hypoxic conditions; thus 
suggesting to be the most suitable vehicles for our future analyses. 
Moreover, we evaluated BM-MSCs tropism to GBM derived cells modulated by 
oxygen levels or by the presence and absence of soluble factors shown to be able to 
stimulate astro-glial and neuronal differentiation, such as BMP2 and WNT3a 
respectively. Indeed, BMPs are members of the Transforming Growth Factor-β (TGF-β) 
Superfamily shown to stimulate both proliferation and mitotic arrest, to promote astro-
glial differentiation reducing cell growth and increasing portion of GFAP
+
 cells. Wnt3a 
ligand mediates neuronal differentiation and proliferation inhibition of GBM cells and 
this phenomenon is enhanced under hypoxic conditions. 
hMSCs tropism was assessed both when primary GBM –derived cells were pre-treated 
alternatively with BMP2 or WNT3a and when such factors were delivered towards 
GBM cells. Our data demonstrated pro-differentiating molecules as enhancing agents of 
hMSCs migratory properties, especially in hypoxia.  
Experiments involving viruses were performed both on HSV1 wild type and R3616 to 
test the ability to replicate in and to kill GSCs. As expected for a neuroattenuated virus, 
R3616 replication in GSCs was widely impaired and the killing ability were decreased 
compared to the wild type. Both viruses were also employed to test their replication 
capacity and cytotoxicity in BM-MSCs. Compared to HSV1 wild type, R3616 retained 
impaired replication efficiency and attenuated killing ability in hMSCs.  
BM-MSCs inherent tropism was also investigated in GSCs infected with HSV1 wild 
type or R3616. Interestingly, we found that GSCs R3616 infected significantly 
increased the migratory properties of BM-MSCs. 
In conclusion, these findings support the use of BM-MSCs as a promising cell vehicle 
candidate for tumor-specific delivery and open the way to the development of 
engineered BMPs-expressing MSCs to further assays in GBM -derived cells. 
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Additionally, the R3616 ability to kill GSCs encourages next efforts to combine both 
methods to obtain an efficient strategy to selectively target GSCs. Our preliminary data 
have already demonstrated that co-treatment of R3616 and BMP2 increases the 
differentiation markers expression. Accordingly, BM-MSCs retained a preferential 
inherent homing towards more differentiated cells. 
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SOMMARIO 
 
Il Gliobalstoma multiforme (GBM) è il più comune e maligno dei tumori 
cerebrali nell’adulto, caratterizzato da una rapida crescita, proliferazione vascolare e 
diffusa infiltrazione nel parenchima cerebrale. Nonostante negli ultimi anni siano stati 
fatti notevoli progressi terapeutici che includono la rimozione chirurgica della massa, 
seguita da radioterapia e chemioterapia, la prognosi ancora oggi permane 
particolarmente infausta con una sopravvivenza media di circa 14 mesi dalla diagnosi. 
Ciò pare sia associato anche all’esistenza nel cervello di una popolazione di cellule 
definita “Cancer Stem Cells” (CSCs). Tali cellule vengono definite Glioma Stem Cells 
(GSCs) e, al pari delle normali cellule neuronali staminali, sono caratterizzate da 
capacità di auto-rinnovamento, sono multipotenti, nonché tumorigeniche in vivo. 
Inoltre, le GSCs sembrano svolgere un ruolo importante nell’insorgenza e la 
progressione del GBM, contribuendo appunto alla resistenza alla chemioterapia e alla 
radioterapia, oltre ad essere responsabili delle recidive di tale tumore. A fronte di tutto 
ciò, si rende quindi necessario più che mai lo sviluppo di nuove strategie terapeutiche 
che siano particolarmente selettive e mirate a colpire la popolazione delle GSCs. In 
questo lavoro di tesi, abbiamo posto la nostra attenzione in particolare a due strategie: 
- L’uso delle Cellule Staminali Mesenchimali (MSCs) come sistemi di delivery 
cellulari per composti attivi contro i tumori cerebrali sfruttando il loro intrinseco 
tropismo per il letto tumorale per effetto di citochine e chemochine rilasciate dai 
tessuti infiltrati. 
- L’utilizzo di un virus oncolitico di tipo herpetico, R3616, ingegnerizzato per 
colpire selettivamente le cellule tumorali e non causare neurovirulenza, essendo 
stato deleto dei geni γ34.5 responsabili dell’insorgenza di encefalite. L’effetto di 
queste delezioni inoltre comporta inibita autofagia e attenuata replicazione anche 
nelle stesse GSCs.  
Le GSCs utilizzate per i nostri esperimenti sono state derivate da biopsie di pazienti 
affetti da GBM e coltivate in adesione al 21% che al 2% di O2 o in sospensione al 21% 
di O2 come neurosfere secondo i parametri previsti da protocolli accettati in letteratura. 
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Le cellule cresciute come neurosfere sono state caratterizzate fenotipicamente con 
alcuni dei più comuni marcatori di staminalità, tra cui il CD133, la Nestina, Sox2 e il 
CD44.  
Per gli esperimenti di delivery cellulari sono state inizialmente valutate le hMSCs 
isolate dai campioni di midollo osseo derivanti da donatori sani (BM-MSCs) e da 
tessuto adiposo (AT-MSCs) cerebrale prelevato durante l’intervento di rimozione 
chirurgica di GBM dello stesso paziente. Le MSCs appartenenti ad entrambe le fonti 
sono state immuno-fenotipicamente caratterizzate e coltivate in ipossia e in normossia al 
fine di valutarne la capacità e l’efficienza di crescita ricreando il tipico microambiente 
del GBM verso cui poi le cellule dovrebbero essere fatte migrare. Saggi a.) di crescita, 
b.) di differenziamento in vitro e c.) di migrazione hanno evidenziato come le BM-
MSCs migrino in maniera più efficiente e selettiva delle AT-MSCs verso le cellule 
tumorali, specie in condizioni ipossiche. Pertanto, le BM-MSCs sono state scelte come 
modello di delivery cellulare per proseguire i nostri esperimenti. Inoltre abbiamo visto 
come questa migrazione avvenga anche verso cellule tumorali pre-trattate con fattori 
morfogeni ad effetto pro-differenziativo nei gliomi, quali BMP2 e WNT3a. Le BMPs 
sono membri della Famiglia del Transforming Growth Factor-β (TGF-β), e sono in 
grado a livello cerebrale di portare ad arresto del flusso mitotico, blocco della 
proliferazione cellulare e ad un’azione di differenziamento in senso gliale aumentando 
la percentuale di cellule a fenotipo GFAP
+
. Il Wnt3a è noto essere invece un ligando in 
grado di promuovere il differenziamento in senso neuronale e inibire la proliferazione 
cellulare, specie in ipossia.  
Per gli esperimenti di Virotherapy si è innanzitutto valutata la capacità di replicazione e 
di morte cellulare del virus deleto R3616 paragonandola all’ efficienza dell’HSV1 wild 
type nelle GSCs. R3616 ha dimostrato un’efficienza di replicazione e di uccisione 
attenuata rispetto all’HSV1 wild type. Entrambi i virus sono stati poi testati per valutare 
la capacità di replicazione e di killing nelle BM-MSCs. Rispetto all’ HSV1 wild type, 
R3616 ha riportato una minore citotossicità e compromessa capacità di replicazione.  
L’efficienza di migrazione delle BM-MSCs è stata poi valutata in GSCs infettate sia con 
HSV1 wt, sia con R3616. In entrambi i casi è trovato un aumentato tropismo delle BM-
MSCs, specie quando le GSCs erano state infettate con R3616.  
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In conclusione in questo lavoro, proponiamo l’utilizzo di cellule staminali mesenchimali 
come veicolo per trattare il Glioblastoma con molecole fisiologiche ad azione pro-
differenziativa così da aumentarne la risposta agli attuali trattamenti chemioterapici.  
Inoltre, l’aumentata efficienza di migrazione insieme alla capacità di uccisione selettiva 
delle GSCs riscontrata nell’utilizzo di R3616, incoraggiano a un trattamento di 
combinazione dei due possibili approcci. Risultati preliminari hanno già evidenziato 
come GSCs infettate con R3616 e trattate con BMP2 siano in grado di aumentare 
l’espressione dei canonici marcatori di differenziamento cellulare e ciò incoraggia a 
valutare se tale effetto possa stimolare ulteriormente l’efficienza e aumentare la 
selettività di migrazione delle BM-MSCs. 
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1.  INTRODUCTION 
1.1 CLASSIFICATION OF BRAIN TUMORS 
 Primary Brain Tumors are a heterogeneous group of malignancies that originate 
and reside within the Central Nervous System (CNS) (Germano et al., 2010).  
In Europe, about 27,700 new CNS tumors are diagnosed (Crocetti et al., 2012). The 
incidence of primary CNS cancers ranges from 4.5 to 11.2 cases per 100,000 men and 
from 1.6 to 8.5 per 100,000 women according to the data provided by the Surveillance 
of Rare Cancers in Europe (RARECARE; www.rarecare.eu) (Crocetti et al., 2012). The 
peak of incidence is 18.5/100,000 among people over 65 years (Crocetti et al., 2012) 
with the 5-year survival rate of 17% for males and 19% for females (Sant et al., 2009) 
and differences across European regions (Crocetti et al., 2012). 
Among CNS tumors, gliomas are the most common primary malignancies. They arise 
from the constituent glial cells of the brain (Masui et al., 2012). that supply nutrients, 
oxygen and maintain the physiological homeostasis. According to their morphological 
appearance gliomas are defined as astrocytomas, composed predominantly of 
astrocytes, oligodendrogliomas, composed predominantly of oligodendrocytes, and 
tumors containing a mixtures of various glial cells (i.e. oligoastrocytomas) and 
ependymal cells (i.e. ependymomas) (Dolecek et al., 2012). 
Among them, astrocytomas are the most common CNS tumors, with an incidence rate 
of 4.8 per 100,000 per year in Europe (Crocetti et al., 2012). 
The World Health Organization (WHO) grading system further classifies gliomas into 
four different grades (I–IV) based on the degree of malignancy, as determined by 
histopathological criteria (Louis et al., 2007): 
 grade I: pilocytic astrocytoma, 
 grade II: diffuse astrocytoma, 
 grade III: anaplastic astrocytoma,  
 grade IV: Glioblastoma Multiforme. 
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Grade I astrocytomas (pilocytic astrocytomas) are slow-growing, relatively 
circumscribed and benign tumors.  
Grade II (diffuse astrocytomas), so-called low grade astrocytomas, are histologically 
characterized by moderate cellularity, mild nuclear atypia, rare or absent mitotic figures 
and they are moderately proliferative and invasive. Conversely, grade III (anaplastic 
astrocytomas) and IV (glioblastoma multiforme) astrocytomas are defined as high-grade 
gliomas (Nager et al., 2012).  
Grade III (anaplastic astrocytoma) tumors are characterized by increased cellularity, 
nuclear atypia, and mitotic activity. These tumors are more proliferative and infiltrative 
compared with grade II gliomas.  
Grade IV astrocytomas display uncontrolled cellular proliferation, diffuse infiltration, 
robust angiogenesis, necrotic tissue and hypoxic areas (Westphal and Lamszus, 2011). 
 
1.2 GLIOBLASTOMA MULTIFORME (GBM) 
 Glioblastoma Multiforme (GBM) is the most aggressive and highly lethal form 
of primary brain tumor in adults. In industrialized countries, the annual incidence of 
GBM is 2-3 cases per 100,000 people (Louis et al., 2007) (Wen and Kesari, 2008), with 
a median survival of 14.6 months after diagnosis (Dolecek et al., 2012) (Stopschinski et 
al., 2013) (Germano et al., 2010) (Nager et al., 2012).  
No underlying causes have been identified for GBMs. There are few known risk factors, 
such as the exposure to ionizing radiation (Wen and Kesari, 2008) and the exposure to 
electromagnetic fields (Crocetti et al., 2012); no preventive strategies and no practical 
methods for screening (Dirks, 2010). Only about the 5% of patients present family 
history of gliomas, but in most of these familial cases no common genetic aberrations 
have been currently identified (Wen and Kesari, 2008). GBM affects preferentially men 
than women and it is more common in whites than in blacks. The median age of patients 
at the time of diagnosis is approximately 64 years (Wen and Kesari, 2008) (Fisher et al., 
2007). Most common symptoms are headache, nausea, focal neurological deficits 
(visual impairment), alterations in mental status or epileptic seizures depending on the 
localization of the tumor, intracranial pressure and grade of infiltration into the brain 
parenchyma (Louis et al., 2007). 
1. Introduction 
11 
 
GBM is usually located in the cerebral hemispheres (Robert and Wastie, 2008). It can 
grow quickly and become very large before producing symptoms. About 50% of 
identified GBMs occupy more than one lobe of a hemisphere, or are expanded 
bilaterally (Ohgaki and Kleihues, 2005a) (Robert and Wastie, 2008). GBMs may even 
extend to the meningeal or ventricular wall and only rarely malignant cells may spread 
to the spinal cord. Extracranial metastasis of GBM beyond the CNS is extremely rare 
event, with a reported frequency of only 0.44% (Robert and Wastie, 2008).  
In Figure 1. is shown an example of the Magnetic Resonance Imaging (MRI) scan in a 
patient affected of GBM at the left hemisphere (Dirks, 2008). 
 
 
 
 
 
 
 
 
 
 
Figure 1. Magnetic Resonance Imaging (MRI) of GBM-affected patient at the left-
hemisphere (Dirks, 2008). 
 
GBM can occur as “primary” or “secondary” tumors based on clinical characteristics 
(Nager et al., 2012) (Westphal and Lamszus, 2011): 
 primary or “de novo” GBM, representing the majority of GBM cases, arise 
without any prior evidence of a lower-grade precursor lesion and it is detected 
more commonly in older patients (mean age of 62 years); 
 secondary GBM, develops progressively from a lower-grade glioma and 
typically occur in younger patients (median age of 45 years), generally over a 
period of 5–10 years. 
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Such distinction also reflects mutations and perturbed signaling pathways important for 
GBM progression (Ohgaki and Kleihues, 2005b); nonetheless, primary and secondary 
GBMs remain morphologically indistinguishable and respond similarly to currently 
conventional therapies (Wen and Kesari, 2008). 
The majority of GBM present genetic alterations that occur through epigenetic 
modifications, point mutations, translocations, amplifications, or deletions leading to a 
deregulated signaling pathway and contributing to a so heterogeneous and aggressive 
tumorigenesis (Chen et al., 2012). 
On the base of gene expression profile data, The Cancer Genome Atlas (TCGA) 
classified GBM into four different molecular subgroups (Nigro et al., 2005): (a.) 
Proneural, (b.) Neural, (c.) Classical and (d.) Mesenchymal (Stopschinski et al., 2013) 
(Sulman et al., 2009) (Lei et al., 2011) (Parsons et al., 2008).  
Interestingly, each of these subtypes shown an enrichment of gene expression signatures 
from distinct neural lineages, implying that the expression patterns of the different 
subtypes may reflect the phenotype of their specific cells of origin (Noushmehr et al., 
2010). These molecular signatures were associated with tumor aggressiveness and 
disease progression and could be related to the different signaling pathways implicated 
in the gliomagenesis.  
Notably, proneural GBM comprised patients with primary diagnosis, younger age and 
better clinical outcome; mesenchymal GBM showed older patients and patient with 
tumor relapse (Stopschinski et al., 2013). 
 
 
1.3 GBM TREATMENTs  
 The standard of care for newly diagnosed GBM involves surgical resection, 
radiotherapy (60 Gy over a period of 6 weeks) with concomitant chemotherapy with 
Temozolomide (Temodal 
TM
) (75 mg per square meter of body-surface area per day for 
6 weeks) followed by adjuvant chemotherapy with Temozolomide (TMZ), (150 to 200 
mg per square meter per day for 5 days every 28 days for 6 cycles), according to The 
European Organization for Research and Treatment of Cancer (EORTC) and the 
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National Cancer Institute of Canada (NCIC) regime published by Stupp in 2005 (Stupp 
et al., 2005) (Stopschinski et al., 2013). 
As reported by Stupp et al. (Stupp et al., 2005) (Stupp et al., 2009a), the combination of 
radiotherapy and TMZ had an acceptable side-effect profile and, compared with 
radiotherapy alone treatment (60 Gy over a period of 6 weeks), increased the median 
survival from 12.1 to 14.6 months (Stupp et al., 2009a) (Wen and Kesari, 2008) (Weller 
et al., 2010). In addition, the survival rate at 2 years among the patients who received 
radiotherapy plus TMZ was significantly greater than the rate among the patients who 
received radiotherapy alone (27.2% vs. 10.9%).  
Beyond the standard of care treatment, another chemotherapeutic approach for GBM 
involves the implantation of biodegradable polymers (wafers) containing Carmustine 
(Gliadel Wafers, MGI Pharma), at the time of surgical resection of the tumor. Wafers 
are implanted in the surgical cave and positioned in tight contact with the brain surface 
infiltrated by the tumor. Each wafer, 1.45 cm in diameter and 200 mg weight, contains 
7.7 mg of Carmustine (Fleming and Saltzman, 2002). 
The aim of the treatment with these polymers, which release Carmustine gradually over 
the course of several weeks, is to kill residual tumor cells.  
In a randomized, placebo-controlled trial that investigated the use of Carmustine 
polymers in patients with newly diagnosed malignant gliomas, median survival 
increased from 11.6 months to 13.9 months at 2 years (Wen and Kesari, 2008) 
(Westphal et al., 2003).  
TMZ and Carmustine are two alkylating agents. TMZ is administered orally as a 
prodrug that at physiological pH hydrolyzes spontaneously to its active metabolite: the 
5-(3-metyltriazen-1-yl)imidazole-4-carboxamide (MTIC). MTIC causes DNA damage 
by metilating the O6- position of guanine, resulting in a mismatch with thymine in 
double-strand DNA and activation of the mismatch repair system for cytotoxic effect 
(Weller et al., 2010) (Stopschinski et al., 2013).  
The efficacy of TMZ has been reported (Hegi et al., 2005) (Stupp et al., 2009a) to be 
dependent on the methylation status of the promoter for O6-methylguanine-DNA 
methyltransferase (MGMT), a DNA repairing enzyme that neutralizes the toxic effects 
of TMZ by removing alkyl groups from DNA. If the promoter is methylated, the 
MGMT gene is silenced, thus the response to therapy will be greater and prolong patient 
survival (Stupp et al., 2009a) (Darefsky et al., 2012). 
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Carmustine (1,3-bis 2-chloroethyl)-1-nitrosourea or BCNU) belongs to the nitrosureas 
family that, by a cross-linking to guanine and adenine bases, cause DNA strand breaks 
during mitosis. 
Despite all therapeutics advances, GBM still remains a lethal disease. Indeed, the 
majority of GBMs rapidly recur within 2–3 cm of the original tumor site, giving rise to 
relapses with an even more aggressive and resistant phenotype, unequivocally affecting 
patient's outcome (Wen and Kesari, 2008). 
These failures reflect the highly infiltrative nature of GBM, the heterogeneous 
cytoarchitecture consisting in normoxic and hypoxic cells and necrotic areas. In 
addition, Blood Brain Barrier (BBB) protects the CNS, preventing many systemically 
administered chemotherapics to reach tumor sites. 
Among all these features, increasing evidences indicate the existence of a fraction of 
cancer cells with stem-like properties in GBM (Ignatova et al., 2002) (Hemmati et al., 
2003) (Galli et al., 2004) (Singh et al., 2004a; Singh et al., 2004b); this hypothesis has 
already been described for leukemia (Bonnet and Dick, 1997), breast (Al-Hajj et al., 
2003), pancreas (Esposito et al., 2002) and colon (Ricci-Vitiani et al., 2007) cancers.  
These cells are called GBM stem cells (GSCs) and are characterized by the self-renewal 
capacity, tumorigenicity, stem cell markers expression and ability to escape to 
conventional therapies.  
 
1.4 “CANCER STEM CELLS HYPOTHESIS”  
 The “cancer stem cells hypothesis” suggests that only a distinct sub population 
of tumor cells, named cancer stem-cell (CSCs) are able to reconstitute the cellular 
heterogeneity typical of the original tumor (Maugeri-Sacca et al., 2013) (Stopschinski et 
al., 2013).  
Resembling normal stem cells, CSCs are characterized by: (a.) asymmetric cell division, 
(b.) infinite growth, (c.) multipotency, (d.) the capability to differentiate into 
proliferating progenitor-like and more differentiated cells and (e.) tumorigenicity (Reya 
et al., 2001) (Bao et al., 2006a; Bao et al., 2006b) (Visvader and Lindeman, 2008).  
This connotation implies a “hierarchical model”, organized in a pyramidal manner with 
few CSCs at the apex representing the founders of the entire population (Figure 2.A.) 
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(Maugeri-Sacca et al., 2013) (Stopschinski et al., 2013). Nowadays, growing evidences 
support a more plastic “clonal-hierarchical” model where CSCs and their progeny may 
retain or acquire stem-like properties under the microenvironmental stimuli including 
hypoxia, low pH and exposure to paracrine-acting signals (Figure.2.B.) (Maugeri-Sacca 
et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Models proposed to explain the origin and evolution of cancer. The 
“Hierarchical CSCs” model originally postulated that a stem-like cell located at the apex of 
the tumor pyramid is the precursor of the whole tumor population (Panel A.). The 
combined “Clonal-Hierarchical stem cell” model suggests that CSCs could undergo clonal 
evolution, and therefore multiple CSC clones coexisted within the tumor (Maugeri-Sacca et 
al., 2013) (Stopschinski et al., 2013) (Panel B.).  
 
 
To date, there are increasing evidence suggesting the presence of stem cell-like tumor 
cells within GBM, thus so-called Glioblastoma stem cells (GSCs) share several 
properties with their Neural Stem Cells (NSCs) counterparts (Dirks, 2008).  
NSCs are pluripotent cells located in the dentate gyrus of the hippocampus and in the 
sub-ventricular zone (SVZ) of the forebrain lateral ventricles (Weiss et al., 1996) (Gage, 
A. 
B. 
1. Introduction 
16 
 
1998) (Curtis et al., 2007) (Sanai et al., 2004). According to the stem cells hypothesis, 
GSCs are thought to be able of giving rise to cells that express markers of primary 
neurons and glial cells, such as astrocytes and oligodendrocytes, as well as being able to 
self-renew (Galli et al., 2004).  
Unlike NSCs counterparts (Figure 3. A.), GSCs function in a dysregulated manner and 
are thereby able to repopulate all the cell-types contributing to glioma proliferation 
(Gursel et al., 2011), to create heterogeneity and to promote invasion (Persano et al., 
2013) (Figure3. B.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 3. Stem cell hierarchy in normal brain (Panel A.) and brain tumors (Panel B.) 
(Dirks, 2008). Rare stem cells in the brain are able to self-renew to maintain themselves and 
also generate progenitors that proliferate and differentiate into mature cells that form the 
highly organized brain parenchyma. The hierarchy remains poorly defined in terms of 
markers that unequivocally define stem cells from progenitor cells. Brain tumors are also 
organized as a hierarchy based on cancer stem cells. Cancer stem cells are dysregulated in 
terms of self-renewal and proliferation and they aberrantly differentiate into cells that form 
the bulk of the disorganized cancer tissues. 
 
 
 
B. 
A. 
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Strict criteria have been necessary to identify GSCs, such as (Vescovi et al., 2006): 
 
 a.) Expression of a repertoire of markers common to stem cells. CD133 
(Prominin-1 surface antigen) expression, originally broadly investigated for GSCs 
characterization and targeting (Uchida et al., 2000), appears to date not the unique 
hallmark for GSCs identification (Singh et al., 2004a) (Beier et al., 2007). The 
validation of novel stem markers and their combined use might add a further level of 
reliability to current isolation protocols (Dirks, 2008). This repertoire include for 
example: Nestin (Tohyama et al., 1992) (Dahlstrand et al., 1992), the sex determining 
region Y box 2 transcription factor (Sox2) (Cai et al., 2002) (Hemmati et al., 2003), 
BMI1 (Hayry et al., 2008) and CXCR4 (Zheng et al., 2012).  
 
 b.) The ability to self-renew and to differentiate into multiple lineages (i.e. 
neurons, astrocytes and oligodendrocytes) (Reynolds and Weiss, 1992) is a hallmark of 
stem cells. Self-renewal of stem cells is in vitro determined through neurosphere-
forming ability when a single cell is grown in serum free medium supplemented with 
EGF and FGF as growth factors (Galli et al., 2004) (Gursel et al., 2011). Indeed, by 
definition, a neurosphere represents a clonal single cell-derived floating cluster of 
proliferating cells (Reynolds and Weiss, 1992) (Reynolds and Weiss, 1996) (Tropepe et 
al., 1999). 
 c.) Tumorigenicity of GSCs: capability to recapitulate the tumor of patient from 
which the cells were derived upon injection into immune-compromised mice (Galli et 
al., 2004) (Dirks, 2008). 
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1.5 GLIOBLASTOMA STEM-LIKE CULTURES 
 
Primary GBM derived cells can be cultured: 
 
a.) in adhesion (Conti et al., 2005) (Sun et al., 2008), on laminin (Pollard et al., 
2009) or fibronectin-coated plates (Pistollato et al., 2011); 
b.) in neurosphere suspension conditions (Reynolds and Weiss, 1992) (Reynolds 
and Weiss, 1996). 
 
In Figure 4. is represented an example of GBM stem-like cells grown in adhesion 
(Panel A.) or as neurospheres (Panel B.) (Pollard et al., 2009). 
 
 
 
 
 
 
 
 
 
Figure 4. GBM stem like cells cultured in adhesion (Panel A.) and in suspension as 
neurospheres (Panel B.) (Pollard et al., 2009). 
 
 
GBM-derived cells can be grown in suspension as neurospheres in serum-free media 
supplemented with EGF and FGF growth factors (Galli et al., 2004) (Reynolds and 
Weiss, 1992) (Reynolds and Weiss, 1996). The neurosphere represents, by definition, a 
clonal single cell-derived floating cluster of proliferating cells (Reynolds and Weiss, 
1992) (Reynolds and Weiss, 1996) (Tropepe et al., 1999).  
The advantage of this modeling is a greater preservation of the native phenotype, 
genotype and karyotype; not preserved in adherent cells modeling due to the aberrations 
they can accumulate over the several passages (Gursel et al., 2011) (Gunther et al., 
2008) (Chen et al., 2012). However, it has been recently proposed by Pollard an 
adaptation to the neurosphere model (Pollard et al., 2009) to facilitate high-throughput 
A.                                 B.  
1. Introduction 
19 
 
screening and to also overcome some of the issues of neurosphere culture, such as 
inadvertent fusion among spheres and the lack of access to nutrients within the sphere 
(Pollard et al., 2009) (Reynolds and Rietze, 2005) (Singec et al., 2006) (Suslov et al., 
2002). Moreover, neurospheres might contain more differentiated progeny and regions 
of cell death due to their inherent condensed structure, which would hinder the diffusion 
of the growth factors to the innermost cells (Woolard and Fine, 2009). This could be 
achieved by culturing cells on laminin -coated flasks (Pollard et al., 2009). In this way, 
cells that would normally form neurospheres, grow as an adherent culture, which allows 
of all the cells equal access to growth factors. Additionally, such cells grown in 
adhesion seem to be less heterogeneous than neurosphere cultures, and almost all of 
them seem to express canonical stem cell markers, such as Sox2, Nestin, CD133 with 
minimal expression of differentiation markers (Pollard et al., 2009). An additional issue 
in suspension culture might be represent by the mechanical and chemical dissociation 
that could entailed the introduction of cellular debris and increased cells death (Gursel 
et al., 2011). Nevertheless, it is also important to remind that it has been demonstrated 
that calf serum or serum substitute (Pistollato et al., 2011) as well as trypsin treatment to 
detached cells grown in adhesion induce cell differentiation (Singh et al., 2004b).  
Although GSCs culture grown as spheres represent the ideal modeling for the in vitro 
study (Reynolds and Weiss, 1992); isolation, maintenance and experimentation on these 
cells may be pursued culturing cells both in adhesion and in suspension conditions. 
However, there are experimental criteria widely recognized as necessary to define 
GSCs, that cannot exclude the self-renewal capacity, tumorigenicity (Galli et al., 2004) 
(Reynolds and Weiss, 1992), likewise the presence of the markers common to stem cells 
(Dirks, 2008) (Gursel et al., 2011).  
 
In our experiments we used both protocols, following the guidelines designed by Dr. 
Pistollato and co-workers (Pistollato et al., 2011) for the data obtained in the Laboratory 
of Oncohematology (Dept. of Woman and Child, University of Padova); whereas, for 
results collected in the Laboratory of Microbiology and Virology (Dept. of Molecular 
Medicine, University of Padova) cells were grown as spheres under suspension 
conditions (Reynolds and Weiss, 1992). 
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1.6 THERAPEUTIC TARGETING OF GSCS 
 All features outlined above highlight the urgent need to develop novel and more 
effective therapies based on the specific targeting of GSCs, while sparing normal neural 
cells. Moreover, growing evidence indicates GSCs are less vulnerable to chemo and 
radiotherapy due to their ability to correct genetic lesions generated by DNA alkylating 
agent such as TMZ (Bao et al., 2006a) (Maugeri-Sacca et al., 2013).  
Thus, it is possible that GSCs contribute to tumor repopulation after conventional 
therapies. 
During last years several approaches have been investigated to selectively target GSCs 
population. Remarkable advances in the genetics and biology of gliomas, have 
contributed to our understanding of tumor development and progression and have given 
rise to novel therapeutic approaches. Gene therapy has been one area of focus, using 
vectors, often viruses, to insert immune-stimulating or drug-susceptibility genes 
(Boviatsis et al., 1994). Virotherapy employed genetically engineered viruses, such as 
HSV type 1 (HSV1), to establish productive infection only in dividing tumor cells 
without injuring adjacent normal brain tissue (Martuza et al., 1991).  
However, taking into account the heterogeneity identified in GBMs, new therapeutical 
approaches cannot exclude genomic abnormalities and the peculiar tumor 
microenvironment. Such microenvironment, formed by supporting cells, extracellular 
matrix components, and other factors that maintain GSCs in a self-renewing, stem-like 
state, resembles the stem cell niche (Calvi et al., 2003) (Dirks, 2008). 
Thus, therapeutical strategies that target GBM microenvironment or force GSCs to 
differentiate into lineage specific progenitors and mature astrocytes may be worthy 
pursued.  
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1.6.1  TARGETING GSCS BY INDUCING  DIFFERENTIATION 
Focus on Bone Morphogenetic Proteins (BMPs) 
 Therapy forcing GSCs to differentiate into a more commitment lineage might be 
a promising and non-cytotoxic strategy for GSCs targeting. In this regard, in our study 
we have focused our attention to BMPs. BMPs are members of the Transforming 
Growth Factor-β (TGF-β) Superfamily of secreted ligands. The prototypic receptors for 
BMP in mammals are the type II receptor, BMPR2, and type I receptors, BMPR1A and 
BMPR1B (Shou et al., 2002). BMP2 and BMP4, binding to BMPR1A, can act as 
neuroepithelial proliferation signals at very early stages of embryonic central nervous 
system development. Later, in development, they induce neuronal and astrocytic 
differentiation of NSCs and this event coinciding with the increased expression of 
BMPR1B (Shou et al., 2002). The most common TGF-β signal transduction pathway 
involves SMAD proteins (Heldin et al., 1997) and begins when a TGF-β or BMP family 
member, such as BMP2 or BMP4, bind to the BMPRI and then recruit the BMPRII. 
Activation of the receptor complex leads to phosphorylation of the receptors and 
subsequent phosphorylation of Smad1, Smad5, or Smad8 (receptor regulated SMAD 
proteins), allowing them to form a complex with Smad4 (coSMAD). This heteromeric 
complex translocates to the nucleus, to target BMP-regulated genes through interaction 
with co-activators or repressors. Smad 6 and Smad7 may act similarly to inhibit the 
BMP pathway through interactions with the receptor complex and thus inhibiting R-
Smad activation. TGF-β and BMP pathways induce the expression of proteins involved 
in proliferation, differentiation, survival and apoptosis (Massague et al., 2005). In 
Figure 5. is reported a schematic model of the BMPs pathway. 
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Figure 5. BMP Signaling Pathway (Villapol, DOI: 10.5772/53941). BMP2 and BMP4, 
bind to their type I receptor BMPRI before recruiting the type II receptor BMPRII. 
Activation of the receptor complex leads to phosphorylation of the receptors and 
subsequent phosphorylation of Smad1, Smad5, or Smad8, allowing them to form a 
complex with Smad4. This heteromeric complex translocates to the nucleus, to target 
BMP-regulated genes through interaction with co-activators or repressors. Smad6 and 
Smad7 may act similarly to inhibit the BMP pathway through interactions with the receptor 
complex and thus inhibiting R-Smad activation. TGF-β and BMP pathways induce the 
expression of proteins involved in proliferation, differentiation, survival and apoptosis. 
 
BMP2 (Pistollato et al., 2009a), BMP4 (Piccirillo et al., 2009) (Piccirillo et al., 2006) 
and BMP7 (Tate et al., 2012) have been already employed as pro-differentiating factors 
for GBM treatment demonstrating in vitro cell growth arrest and astro-glial 
differentiation and promoting in vivo tumor growth inhibition (Piccirillo et al., 2009) 
(Piccirillo et al., 2006) (Kolenda et al., 2011). Nevertheless, almost the 20% of GBMs 
display epigenetic silencing of BMPR1B. Since these patients should not be affected by 
BMP pro-differentiating effects the therapeutic promise of BMPs treatment must be 
view with caution and proposed only for a subset of selected GBM patients expressing 
BMPR1B (Persano et al., 2013).  
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1.6.2 Focus on Wingless Type (WNT) proteins  
 
Another way of forcing GSCs to differentiate into a more commitment lineage seem to 
be related to the Wingless type (WNT) protein pathway. Wnt factors are a family of 19 
secreted glycoproteins of around 40 kDa in size (Li et al., 2012). During embryonic 
development Wnt critically contributes to the establishment of the body axis and organ 
development. In adult organs, the canonical Wnt signaling pathway displays important 
functions, including cell fate determination, cell proliferation, and stem cell 
maintenance (Valenta et al., 2012). It has been recently reported that Wnt activation 
promotes neuronal differentiation of GBM cancer cells under hypoxia by upregulating 
the pro-neuronal genes and by inhibiting the stemness-related pathways (Rampazzo et 
al., 2013). Nevertheless, the role of Wnt activation in regulating brain tumor phenotype 
remains currently controversial and the interaction between Wnt pathway and hypoxic 
signalling in brain tumours remain to be still elucidated.  
 
1.7 The GBM hypoxic niche  
 
Hypoxia is known to control transcription of many genes that are pivotal in 
many aspects of cancer biology (Heddleston et al., 2009) angiogenesis (Bao et al., 
2006b), cell survival, genomic instability (Koshiji et al., 2005), invasion (Harris, 2002), 
chemotherapy and radiation resistance (Vaupel, 2004) (Amberger-Murphy, 2009) and 
glucose metabolism (Semenza, 2010) (Pistollato et al., 2010b) (Figure 6.). 
Hypoxic area of the brain report an oxygen level less than 2.5%; conversely, healthy 
brain tissues have a range between 12.5% to 2.5% O2 (Erecinska and Silver, 2001) 
(Evans et al., 2008). The close connection to oxygen levels and stem cells has been 
widely demonstrated (Bar, 2011) (Heddleston et al., 2009) (Keith and Simon, 2007) 
(Pistollato et al., 2007). Indeed, hypoxia prevents the differentiation of NSCs and 
promotes the self-renewal of CSCs (McCord et al., 2009) (Heddleston et al., 2009). 
Similarly, hypoxic niches are involved in maintaining the stem-like status of GSCs 
(Seidel et al., 2010) (Li et al., 2009) 
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Figure 6. The characteristics of a hypoxic tumor mass (Vaupel P. et al. 2004). 
 
 
The key intracellular molecular system of the hypoxic response is modulated by the 
Hypoxia Inducible Factor (HIF) (Semenza et al., 1995). Three members have been 
recognized: HIF1α, HIF2α and HIF3α.  
HIF1α is ubiquitously expressed and it seem to be induced in both GSCs and non-stem 
cells, whereas HIF2α seem to be up regulated only in GSCs suggesting that its 
inhibition might spare NSCs. Inhibition of HIF factors in GBMs has been shown to be 
extremely effective. Reducing HIF-1α, using siRNA, inhibited the hypoxic response 
and attenuated GBM growth in vitro and in vivo (Gillespie et al., 2007). Similarly, 
targeting either HIF-1α or HIF-2α, reported reduction of VEGF expression in GSCs, 
and most importantly reduced the clonogenicity of CD133-positive cells in vitro and in 
vivo (Heddleston et al., 2009). This point is important as any potential therapy targeting 
HIF activity may not only target hypoxic cancer cells but may target normoxic cancer 
cells as well.  
On this scenario, it is clear how the disruption of a such particular microenvironment 
may provide a new approach for selectively targeting GSCs (Pistollato et al., 2009b). 
Moreover, lowered oxygen levels may repress the differentiative effect of BMPs 
(Pistollato et al., 2007) {Piccirillo, 2009 #378}. Previous studies indicate that distinct 
BMP signaling pathways able to promote differentiation and apoptosis in normal stem 
cells at low oxygen levels, via HIF-1α, de-sensitize GBM cells to BMP activation 
leading to a reduction in canonical SMAD1/5/8 activation (Pistollato et al., 2007) 
(Piccirillo et al., 2009). Importantly, re-exposure at 21% O2 levels resulted in rapid loss 
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of HIF-1α, activation of SMAD1/5/8, and induced differentiation within at least 48h of 
reoxygenation (Pistollato et al., 2007) (Pistollato et al., 2009a).  
Additionally, BMPRs genes are up-regulated in cells cultured under high oxygen 
tensions. Thus, the strongest BMP2 mediated effect at 21% O2 correlate also with an 
increased expression of its receptor. These finding highlight the possibility of BMPs 
molecules to be used as pro-differentiating therapies for GBM, but open the way to 
study pro-differentiating molecules able to modulate GBM cells phenotype also in their 
physiological hypoxic microenvironment (Persano et al., 2013) (Piccirillo et al., 2009).  
Another aspect to take into account is the hypoxia-mediated GSCs resistance to 
radiotherapy (Vaupel, 2004) and chemotherapy (Kolenda et al., 2011) highlighted by an 
increased proliferation and a decreased apoptotic potential (Pistollato et al., 2010a). 
Understanding the interactions between GCSs and the microenvironment balance of the 
niches where they reside will be fundamental to unveil the role of this controversial 
population in tumor initiation, progression, invasion and therapeutic resistance. 
 
1.8 The three-layer concentric model of GBM 
 
During last years, the role of hypoxic niche and how such lowered oxygen 
gradient could modulate GSCs proliferation, phenotype and differentiation have been 
extensively investigated by Dr. Persano and coworkers. By sampling multiple 
intratumoral areas through radiological imaging and image guided surgery, they 
unraveled a GBM phenotypic correlation to the hypoxic gradient, defining a “tumor 
stem cell concentric model niche” (Figure 7.).  
Based on the distance from the anoxic central core, three different layers have been 
identified (Pistollato et al., 2010a) (Persano et al., 2011): a.) the internal core, b.) the 
intermediate, and c.) the peripheral layers. 
The inner core is highly hypoxic and characterized by more immature stem cells 
expressing Nestin and with low proliferation index.  
The intermediate portion is a mildly hypoxic and thin transition area between the 
partially necrotic core and the peripheral layer, with immature and proliferating tumor 
precursor cells.  
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The peripheral layer appears the most vascularized and oxygenated area predominantly 
expressing committed/differentiated cells (Pistollato et al., 2010a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.: Graphic representation summarizing the phenotypic and molecular of the 
three concentric layers model of GBM. Inner portions of tumor mass display more 
immature cancer cells (Nestin+) and account for the highest percentages of cancer stem 
cells identified by CD133 staining. This identified stem cell population is resistant to 
alkylating agents-based chemotherapy in vitro. Peripheral GBM cells show a more 
differentiated phenotype (GFAP+, βIII-tubulin+) with low levels or absence of CD133+ 
cells. These peripheral tumor cells are highly sensitive to Temozolomide (TMZ) (Persano 
et al., 2011). 
 
According to the three concentric layers model, the highest percentage of CD133
+
 cells 
were identified in the inner portion. These cells overexpressed MGMT enzyme and 
shown to be in vitro resistant to TMZ treatment. Conversely, peripheral GBM cells 
displayed a more differentiated phenotype with lower levels or absence of CD133
+ 
cells 
and they resulted highly sensitive to TMZ treatment (Persano et al., 2011). The 
existence of two types of cancer stem cells within different regions of the same human 
GBM was firstly been reported also by other groups (Piccirillo et al., 2009). Thus, the 
concentric distribution of GBM cells within the tumor mass might have important 
implications in the GBM treatment and both diagnostic and therapeutic methods might 
be improved.  
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1.9 STEM CELLS AS DELIVERING STRATEGIES IN GBM 
 Another approach for targeting GSCs uses stem cells to efficiently deliver 
therapeutic genes and their products to brain tumors.  
Stem cells have several characteristics which make them suitable delivery tools. In the 
context of gliomas, three types of stem cells have been explored: a.) embryonic, b.) 
neural and c.) mesenchymal. Moreover, GBM have been reported to attract implanted 
and injected Neural Stem Cells (NSCs) and Mesenchymal Stem Cells (MSCs) (Aboody 
et al., 2000) (Benedetti et al., 2000) (Ehtesham et al., 2002a) (Ehtesham et al., 2002b). 
Due to their origin, NSCs are more suitable as therapeutic delivery vehicles for brain 
tumors than MSCs. Although the experimental results about NSCs are promising 
(Aboody et al., 2008), it is difficult to obtain NSCs from human brains because of 
practical and ethical problems, and there is the inevitable potential of immunological 
incompatibility in allogeneic transplantation.  
MSCs might be used as a practical alternative stem cell source, easy to obtain and to 
engineered (Bexell et al., 2013) (Mundra et al., 2013). The feasibility of using 
autologous MSCs as cell carries appears very attractive because it allows to avoid 
discussion of allograft rejection altogether. Therefore, MSCs represent a promising gene 
or virus delivery vehicle for gliomas.  
 
1.9.1 Focus on Mesenchymal Stem Cells as potential therapeutical 
strategy for GBM 
 MSCs are non-hematopoietic adult multipotent stem cells: they usually express 
CD73, CD90, CD105 and CD271 surface markers; whereas do not express 
hematopoietic lineage markers such as CD14 and CD45 (Bexell et al., 2013) (Keung et 
al., 2013) (Altaner, 2008). They can be isolated from bone marrow (Bruder et al., 1997), 
umbilical cord blood (Erices et al., 2000), adipose tissue (Zuk et al., 2002) (Zuk et al., 
2001), peripheral blood and dental pulp (Pierdomenico et al., 2005) (Kern et al., 2006). 
Despite the origin site, MSCs are defined by their ability to (a) remain plastic adherent; 
(b.) self-renew and (c.) to undergo adipogenic, osteogenic, and chondrogenic 
differentiation (mesenchymal lineages) when maintained under standard culture 
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conditions (Mundra et al., 2013) (Dominici et al., 2006) (Keung et al., 2013) 
(Chamberlain et al., 2007). 
Among MSCs, Adipose Tissue- (AT-MSCs) and Bone Marrow- derived MSCs (BM-
MSCs) have extensively evaluated over last years since both of them offer the most 
accessible source of MSCs for use in research. Although bone marrow is the major 
source of MSCs, adipose tissue is less invasive, less expensive than bone marrow to 
obtain (Locke et al., 2011) (Yoo et al., 2009) and AT-MSCs demonstrated a more 
oncogenic resistance than BM-MSCs when injected in in vivo models (Momin et al., 
2010). 
 
Once intracranially or intravenously administered, MSCs easily cross the BBB and 
migrate throughout normal brain parenchyma, preferentially towards the injured sites. 
This is possible due to their own inherit homing ability toward tumor site (Doucette et 
al., 2011) (Sasportas et al., 2009) (Nakamizo et al., 2005) and mediated at least in part 
by chemokines and other specific tumor-derived growth factors such as the vascular 
endothelial growth factor-A (VEGF-A) and interleukin-8 (IL-8) (Birnbaum et al., 2007) 
(Nakashima et al., 2010) (Doucette et al., 2011) (Nakamizo et al., 2005).  
Moreover, it has been shown that hypoxia increases the in vitro migration capacity of 
MSCs through a number of direct or indirect mechanisms, including modification of 
local factors involved in the maintenance of MSCs within BM or other tissues 
(Rochefort et al., 2006). 
Moreover, compared with all other stem cells employed for cell delivery, MSCs have 
the clinical advantage to be acquired from patients and auto-transfused without fear of 
immune rejection and they are free of ethical concerns (Doucette et al., 2011) 
(Nakamizo et al., 2005) (Mundra et al., 2013 ) (Ahmed et al., 2011) (Kosztowski et al., 
2009) (Ehtesham et al., 2002a) (Ehtesham et al., 2002b) as well. 
Mesenchymal stem cells have been used to deliver a plethora of therapeutic agents to 
glioma including prodrugs, viruses, cytokines and antibodies (Lamfers et al., 2009) 
(Huang et al., 2010).  
Gene-engineered MSCs producing interleukin-18, interleukin-2 and interleukin-12 
infected by Adenoviral vector showed inhibition of glioma growth and prolonged the 
survival of glioma-bearing rats (Nakamura et al., 2004) (Xu et al., 2009) (Hong et al., 
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2009). MSCs transfected with tumor necrosis factor related apoptosis-inducing ligand 
(TRAIL) induced apoptotic activity in vitro and in vivo (Yang et al., 2009) (Choi et al., 
2011). Moreover, in the field of suicide gene therapy, intratumoral injection of MSCs 
transduced with herpes simplex virus-thymidine kinase gene (HSVtk) followed by 
Ganciclovir administration demonstrated a reduction of the tumor size and a significant 
survival prolongation (Amano et al., 2009).  
Further studies are needed to improve both the safety therapeutical window and the 
migration capability of MSCs towards GBM. Indeed, there was no evidence of long-
distance MSCs migration through normal brain tissue towards distant gliomas (Bexell et 
al., 2013). Conflicting data suggested how MSCs may play a role in the formation of 
new tumor blood vessels promoting the invasive nature of the GBMs (Schichor et al., 
2012) or to fuse and transdifferentiate into tumor cells (Schichor et al., 2012). Other 
studies reported a MSCs inhibitory effect on the growth of the tumor (Schichor, et al., 
2012) (Uccelli et al., 2008) (Ramasamy et al., 2007).  
Despite all these controversies, MSCs hold the promising prospect of being ideal 
targeted therapeutic agents as well as cellular carrier in the treatment of GBM. 
 
1.10 VIRO-THERAPY STRATEGIES IN GBM  
 Virotherapy is defined as the delivery of oncolytic viruses for cancer therapy 
(Stopschinski et al., 2013).  
Oncolytic viruses (OVs) are genetically engineered viruses able to replicate in dividing 
cells but are severely impaired for replication in non-dividing cells (Martuza et al., 
1991). Indeed, malignant glioma cells are a dividing tumor cell population, whereas, the 
surrounding normal brain is composed mostly of neurons and glia (Martuza et al., 1991)  
One of the first genetically engineered OV was an oncolytic Herpes Simplex Virus 
(oHSV) (Martuza et al., 1991).  
Herpes Simplex Virus 1 (HSV1) represents a suitable candidate to engender oncolytic 
activity because it infects most cell types in a broad range of species and it is cytolitic 
(Mullen and Tanabe, 2002). In addition, its genome is very large and stable with many 
non-essential genes that contribute to pathogenicity and replication in non-dividing cells 
(Whitley and Roizman, 2001). Thus, HSV genes associated with virulence can be 
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modified, deleted, and replaced with multiple therapeutic transgenes (i.e. immune-
stimulatory molecules (Markert et al., 2012) and prodrug-activating enzymes 
(Braidwood et al., 2009) (Tyminski et al., 2005) without affecting the virus capacity to 
replicate and destroy tumor cells during its lytic phase. Further details about HSV1 will 
be discussed at paragraph 1.11. 
Early generation oHSVs, such as R3616 and 1716 HSVs, were improved by introducing 
multiple deletions and/ or mutations to prevent the reversion to wild-type HSV. 
Nowadays, different oHSVs such as 1716 (Papanastassiou et al., 2002), G207 (Hunter 
et al., 1999) (Mineta et al., 1995) and G47Δ and other several virus species, like 
adenovirus (ONYX-015) (Chiocca et al., 2004), reovirus (REOLYSIN) (Forsyth et al., 
2008), Newcastle disease virus (Freeman et al., 2006), Seneca Valley virus and measles 
virus (Allen et al., 2013) (Todo et al., 2001) have already undergone in clinical trials 
(Senzer et al., 2009).  
Clinical trials based on vaccinia virus for treating malignant gliomas are also ongoing 
(Liu et al., 2007).  
 
To date, no serious adverse effects imputable to oHSV alone have been reported in the 
clinical trials, even when viruses were administered by intracranial injections in the case 
of glioma treatment. However, despite all promising results, further efforts should be 
done to improve the efficiency of OVs.  
Moreover, two hurdles remain preventing the advancement of OV based therapies: 
a.) the host antiviral immune response. Both innate and acquired anti-HSV 
immunity can clear oHSV prematurely to also limit oHSV replication and spread 
(Wakimoto et al., 2003). 
b.) The inefficient viral distribution away from the tumor site. Physical barriers 
such as the extracellular matrix can restrict initial oHSV distribution and 
subsequent spread of virus in the tumor mass, allowing tumor cells to ‘outgrow’. 
Direct intra-tumoral injection of oHSVs has been the preferred route of 
administration, and this limits delivery to accessible tumor sites (Kanai et al., 
2010).  
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1.10.1 Focus on Oncolytic viruses and hypoxia relationship  
As above mentioned, hypoxia plays a fundamental role in GBM invasion, 
aggressiveness and standard therapies resistance (Bar, 2011) (Keith and Simon, 2007) 
(Li et al., 2009) (Seidel et al., 2010).  
The decreased effectiveness of chemo and radiotherapy is in part due to: 
a.) the distally located hypoxic cells, less exposed to systemically administered 
therapies; 
b.) the HIF transcriptional pathways (Amberger-Murphy, 2009).  
Thus, the development of new therapeutic strategies to counteract the hypoxia enhanced 
pathological potency of GSCs became crucial. 
Oncolytic viruses, being selected to kill tumor cells, might represent a promising 
strategy for treating GBM. In particular, recent studies employed two oHSVs, already 
demonstrated safety in clinical trials (Markert et al., 2000): G207 (Aghi et al., 2009) and 
G47Δ (Sgubin et al., 2012). 
Interestingly, the G207 (γ34.5-, ICP6-) exhibited enhanced replication in hypoxic 
environments compared to the wild-type HSV strain F in U87MG glioma cell lines 
(Aghi et al., 2009). 
Furthermore, the G47Δ virus (γ34.5-, ICP6-, ICP47-) retained the ability to infect, 
replicate in and to kill GSCs in hypoxic conditions in vitro and in vivo and importantly, 
counteracted the hypoxia-enhanced stem cell-like properties of GSCs, even if hypoxia 
promoted the CD133
+
 GSC population (Sgubin et al., 2012).  
Treatment with G47Δ should be an effective strategy to eliminate hypoxic GSCs 
resistant to conventional therapies and to improve therapeutic outcomes for GBM 
patients.  
Nevertheless, the HIF response to oHSV infection and mechanisms involving infectivity 
and cytotoxicity in hypoxic conditions needed to be further investigated (Friedman et 
al., 2012).  
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1.11 Herpes simplex virus (HSV) 
1.11.1 Virus structure  
 Herpes simplex virus type 1 (HSV1) is a human natural pathogen 
responsible for localized mucocutaneous lesions and encephalitis (Whitley and 
Roizman, 2001). HSV1 belongs to the alpha-Herpesviridae subfamily of 
herpesviruses. Alpha-Herpesviruses are characterized by a broad host range, rapid 
proliferation, visible cytopathic effects and latency phase in neuronal cells.  
HSV1 is an enveloped, double-stranded DNA (dsDNA) virus. The mature virus 
particles, 120-300 nm size, consist of different components:  a.) an external 
envelope, b.) a tegument, c.) an icosahedral nucleocapsid (100 nm size) and d.) 
a viral genome (Whitley and Roizman, 2001) (Mackem and Roizman, 1982) 
(Figure 8.).  
The envelope contains a host-cell derived trilaminar lipid layer in which are 
embedded 13 different glycoproteins responsible for host cell recognition and 
entry (Mackem and Roizman, 1982) (Batterson and Roizman, 1983). The 
tegument is an amorphous layer, containing at least 20 different proteins with  
structural and regulatory roles at different stages of the virus life cycle. Its 
contains proteins such as virus protein 16 (VP16), VP22, virus shut -off (vhs) 
proteins that are collectively important for viral gene expression (Mackem and 
Roizman, 1982) (Batterson and Roizman, 1983) degradation of host cell mRNA 
(Kwong and Frenkel, 1989), viral particle assembly and inhibition of innate 
immune responses that can repress virus gene expression. The icosahedral 
capsid is composed of 162 capsomers, multiple structural proteins organized in 
150 extravalent and 12 pentavalent, that encapsidate the viral genome 
(Newcomb et al., 1999). 
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The HSV1 genome consists of a 153 kb linear double stranded DNA (Kieff et al., 1971) 
arranged as long (L) and short (S) unique (U) sequences (UL and US) covalently linked 
and flanked by large inverted repeats, the L (RL) and the S (RS) repeat (Figure 9.) 
(Whitley and Roizman, 2001). HSV1 gene nomenclature is based upon the position of 
the gene within the long and short segments. Genes within the long segments are 
designed as UL 1 to UL 56 and genes in the short segments are designed as US 1 and US 
12. The UL region comprises the 82% of the genome (108 kb); the US region is 13 kb. 
Unique region genes are present as single copy; those in the repeated segments are 
present in two copies. In the middle of the UL region is an origin of replication, ORIL; 
whereas, two origin of replication are found in the RS regions. The HSV1 DNA encodes 
about 90 genes; 84 of these transcriptional units encode proteins, divided in essential 
and non-essential functions (at least 47) (Whitley and Roizman, 2001). 
 
 
 
 
 
 
 
 
Figure 9. The genome of HSV1 has a unique long (UL) and a unique short (US) 
regions, flanked by inverted repeated sequences, named LTR. The number of copies 
of LTRs repeat may vary and the repeats allow rearrangements of the unique regions and 
HSV exists as a mixture of four isomers. 
Figure 8. Schematic structure of HSV-1 (www.wisc.edu ).  
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1.11.2 HSV Pathogenesis  
HSV1 can establish either a lytic infection or an asymptomatic, latent, infection 
in sensory neurons and, upon reactivation, causes lesions at or near point of entry into 
the body (Whitley and Roizman, 2001). The lytic cycle of the virus typically causes 
orofacial painful vesicular lesions and, in the most serious cases, encephalitis. 
Encephalitis is an inflammation of the brain that can be asymptomatic or characterized 
by flu-like symptoms, such as fever or severe headache, as well as confused thinking, 
seizures, or problems with senses or movement (Whitley and Roizman, 2001). In most 
cases, people with relatively mild illness recover within a few weeks with no long-term 
complications. 
Nevertheless, severe cases of encephalitis can be life-threatening (Whitley and 
Roizman, 2001). The resulting complications can affect almost all areas of the CNS, 
causing meningitis, myelitis, but also respiratory distress syndrome and acute 
broncospasm (Whitley and Roizman, 2001). 
 
1.11.3 Viral infection 
 During primary infection in epidermis and dermis cells, HSV1 replicates its 
DNA and produces the viral progeny.  
HSV1 enters into the host cells by two different ways: endocytosis and fusion at the 
plasma membrane. To initiate infection, HSV attaches to at least three different classes 
of cell surface receptor. Once virus fused its envelope with the plasma membrane the 
capsid is transported to the nucleus where the DNA is released and a lytic replication 
cycle initiates. HSV replicates by three rounds of transcription that yield: 
a.) α immediate early (α IE) proteins that mainly regulate viral replication; 
b.) β early (β E) proteins that synthesize and package DNA; 
c.) γ late (L) proteins. Among them structural there are virion proteins, 
glycoproteins and tegument proteins (Whitley and Roizman, 2001). L genes are 
divided into two classes: γ1 and γ2. Differently from γ2, γ1 genes do not require 
DNA replication and they are expressed also in presence of replication 
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inhibitors (Zhang and Wagner, 1987). L gene expression peaks around 12-13 
hours post infection. 
After the expression of L genes, viral core and capsid are assembled in the cellular 
nucleus. Viral DNA is reeled into the capsid. Capsids emerge from the nucleus into the 
perivascular space and acquire the tegument proteins (Turcotte et al., 2005). 
1.11.4 Latent infection 
 After an initial lytic replication in epithelial cells of the primary lesion, 
HSV1, as a neurotropic virus, enters sensory neurons of the affected area to 
initiates a lytic replication or to undergo a latent infection characterized by 
minimal gene expression and the inability to detect infectious virus. During 
latency genetically intact genome persists in an inactive, but stable 
nucleosome-associated extrachromosomal state expressing only nucleosome-
associated transcript (LAT) (Cohrs and Gilden, 2001) (Wagner and Bloom, 
1997). The virus can remain in this state until an environmental or a 
physiological stress stimulus, such as fever, UV-light, anxiety, weariness, 
immune-suppression, causes some changes that can trigger transcription 
(Figure 10.). Activated HSV undergoes de novo protein synthesis and viral 
replication (Wagner and Bloom, 1997). Progeny virus travels down the nerve 
axon by anterograde transport back to the primary site of infection ad re -
established infection (Wagner and Bloom, 1997). 
 
 
 
 
 
 
 
 
 
Figure 10. Schematic representation of HSV1 latent phase. 
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1.11.5 Focus on Herpes virus and Virotherapy  
 Since wild-type HSV causes potentially life-threatening encephalitis, attenuation 
is a prerequisite of OVs development. Of considerable interest in connection with this 
disease are the genes that confer upon the virus the capacity to replicate in the central 
nervous system (CNS) tissue. The diploid γ34.5 gene enables the virus to multiply and 
spread in the CNS but it is a not essential gene for viral replication (Chou et al., 1990) 
(Whitley and Roizman, 2001).  
The γ34.5 gene is located in the inverted repeats flanking the long unique sequence (RL) 
of viral DNA and therefore the gene is present in two copies per genome (see details in 
Figure 11.) (Dambach et al., 2006) (Markert et al., 2012) (Chou and Roizman, 1994) 
(Chou et al., 1990). It encodes the ICP34.5 protein, composed by 263 aminoacids and 
consisted of a large amino-terminal domain, a linker or swivel region with the triplet 
Ala-Thr-Pro (ATP codons) repeated 10-times (Chou et al., 1990).  
ICP34.5 protein is the major HSV neurovirulence factor; thus, the deletion of a large 
portion of the gene encoding the ICP34.5 factor is responsible for the neuroattenuated 
phenotype exhibited by the virus. In addition, these deletions inhibit autophagy and 
block virus-induced host protein shutoff, improving the safety profile and minimizing 
the neurotoxicity of HSVs employed in oncolytic virotherapy (Dambach et al., 2006) 
(Kanai et al., 2010) (Aghi and Rabkin, 2005) (Markert et al., 2009).  
 
 
 
 
 
 
 
Figure 11. Schematic diagram of the HSV1 genome (line 1) indicating the relative 
locations of the genes encoding for ICP34.5. The unique long (UL) and unique short (US) 
segments are indicated by lines. The open boxes represent the repeat regions of the 
genome. Above the repeat regions, the terminal and inverted repeats flanking the UL region 
are indicated as TRL and IRL, while those flanking the US region are indicated as TRS and 
IRS. The γ34.5 gene encoding for ICP34.5 protein is located in the TRL and is thus present 
in two copies (filled rectangles, line 3). 
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2. MAIN AIMS OF THE STUDY 
 
 Isolation and characterization of human Bone Marrow (BM-) and Adipose 
Tissue (AT-) Mesenchymal Stem Cells (hMSCs) and cell culture.  
 Characterization of primary GBM stem like cells (GSCs) and cell culture.  
 Evaluation of killing and replication capability of R3616 virus in GSCs. 
 Evaluation of pro-differentiating effects mediated by Bone Morphogenetic 
Protein 2 (BMP2) treatment in GSCs. 
 Evaluation of in vitro migratory properties of BM-MSCs toward GSCs per 
sè, GSCs infected with HSV1 wild type and R3616 viruses or BMP2 pre-
treated . 
 Evaluation of the most suitable candidate for stem cell therapy between 
BM-MSCs and AT-MSCs to further genetically engineered to express 
therapeutic genes (BMP2) as well as conditionally replication competent 
viruses (R3616). 
 Evaluation of combining hMSCs and virotherapy approach to obtain a 
more integrated and efficient strategy to selectively target GSCs. 
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3.1 MATERIALS AND METHODS 
Part I 
3.1.1 Atmosphere-Controlled Incubation 
For culture in 21% oxygen, cells were incubated in a Heraeus BBD 6220 Incubator 
(Thermo Scientific, Asheville, NC, http://www.thermoscientific.com). CO2 was added 
to maintain a 21% O2, 5% CO2 75% N2 balance.  
For 2-5% oxygen culturing, cells were incubated in a INVIVO2 300 Ruskinn chamber 
(Ruskinn C300, Ruskinn Technology Ltd, Baker Company Bridgend UK, 
http://www.ruskinn.com), a hypoxia workstation able to maintain and to control 
temperature, humidity, oxygen and CO2 levels. The system is provided of a chamber for 
maintaining cultures (1.); a gas mixer Q with a gas control software (2.) and a glove box 
to perform cell manipulation (3.) (Figure 12.).  
During all phases of culturing and experimentation the following balance gas levels was 
observed: 2% O2, 5% CO2, 93% N2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: The Invivo2 300 Hypoxia Workstation (Ruskinn C300). The system is 
provided of a chamber for maintaining cultures (1.); a gas mixer Q (2.) and a glove box (3.). 
In our experiments it has been programmed to observe 2% O2, 5% CO2, 93% N2 gas levels 
balance.  
 
 
3. 
1. 
2. 
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3.1.2 Isolation and culture of Human GBM derived Cells (hGBMs) 
 
In the first part of this study, Human Tumor Primary cultures of Glioblastoma (hGBM) 
were used. Samples were derived from 4 tumors taken at surgery (see Table1). 
hGBM10 and hGBM13 cells were used for both normoxic and hypoxic 
experimentation. 
Written informed consent for the donation of tumor brain tissue was obtained from 
patients according to the protocol for the acquisition of human brain tissues obtained 
from the Ethical Committee board of the University of Padova and Padova Academic 
Hospital. Tissues were acquired following the tenets of the Declaration of Helsinki.  
 
code Tumor type Age  Gender  
hGBM01 Glioblastoma 64 Male  
hGBM10 Glioblastoma 75 Female 
hGBM13 Glioblastoma 67 Male 
hGBM83 Glioblastoma 54 Male 
 
Table 1.: Neurosurgical sample collection. 
 
3.1.3 Tissue Dissociation  
 
Tumor tissue was washed with 1X phosphate-buffered saline PBS (10X PBS solution: 
0.58M sodium phosphate dibasic Na2HPO4, 0.17M sodium phosphate monobasic 
NaH2PO4, 0.68M sodium chloride NaCl; pH 7.4), gently minced with a scalpel, and 
resuspended in 1 mL of 1X Hanks’ buffered saline solution (HBSS; Ca2+/Mg2+-free, 
plus Hepes and 1.55 g/L glucose, without bicarbonate, pH 7.2; GIBCO, Monza, MB, 
Italy, http://www.lifetechnologies.com) containing 200 U/ml DNase I (Roche, 
Indianapolis, IN, USA; https://www.roche-applied-science.com), 1 mM MgCl2 and 200 
g/mL Liberase Blendzyme -1 (0.62 WU/ml Collagenase and 66.7 U/ml Dispase, 
Roche) for 1 hr at 37
o
C. Sample was then centrifuged at 1150 rpm for 7 minutes, 
resuspended in fresh HBSS/DNase/MgCl2 without enzyme, and mechanically triturated. 
Upon properly trituration, tissue was centrifuged at 1150 rpm for 7 minutes and cells 
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were resuspended in medium appropriate for further use (Panchision et al., 2007) 
(Pistollato et al., 2007). 
 
3.1.4 Cell Cultures  
 
 hGBM cells were cultured on fibronectin/poly-l-ornithine (GE Healthcare, Little 
Chalfont, U.K.; http://www.gehealthcare.com) coated flasks in Dulbecco’s 
modified Eagle’s medium and Ham’s nutrient mixture F-12 (DMEM-F12, 
GIBCO) ) enriched with 10% of a serum substitute constituted by 1% Bovine 
Serum Albumin, 10 g/mL rh-Insulin, 200 g/mL Human Transferrin (BIT9500 
Stem Cell Technologies, CA, USA; http://www.stemcell.com), 10 ng/ml 
epidermal growth factor (EGF, R&D Systems, Minneapolis, MN, USA, 
http://www.rndsystems.com) and 20 ng/ml basic fibroblast growth factor (bFGF; 
R&D Systems), 2mM L-Glutamine (GIBCO) and 10.000 U/ml streptomycin 
sulfate/ penicillin G (GIBCO). For continuous expansion, one-half of this 
medium was replaced three times per week and cultures were passaged using 
TrypLe Express (Invitrogen, http://www.lifetechnologies.com). To test pro-
differentiating effects on Hutu cells, bone morphogenetic protein 2 (BMP2, 
R&D Systems Inc.) was supplemented in the medium at the concentration of 20 
ng/mL/day for 5 days; whereas, Wnt3a (R&D Systems) treatment was 
performed at the final concentration of 30 ng/mL/day for 7 days. 
 
 human Mesenchymal Stem Cells (hMSCs) from bone marrow (BM-MSCs) of 
healthy donors or from adipose tissue (AT-MSCs) of glioma patients, 
dissociated with the same protocol described above for hGBM specimens, were 
grown and maintained in DMEM medium containing 20% FBS (GIBCO). BM-
MSCs and AT-MSCs were characterized by flow cytometry for the typical 
mesenchymal surface markers and their immuno-phenotype was also tested after 
15 days. Further confirmation for mesenchymal lineage was performed by 
plating cells in adipogenic and osteogenic media, as request by literature 
(Doucette et al., 2011), (Pittenger et al., 1999), (Dominici et al., 2006), 
(Ayatollahi et al., 2012). 
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3.1.5 Flow cytometry analysis  
 
hMSCs were passaged and resuspended in flow cytometry buffer, consisting of 1X 
Hank’s buffer. Cells were counted and diluted at a density of 10×104 cells per 100 µL. 
For surface marker analysis, antibodies against human CD90 (FITC conjugated, 
BioLegend, Milano, Italy; www.biolegend.com), CD44 (FITC conjugated, BD 
Biosciences, San Jose, CA, USA; http://www.bdbiosciences.com), CD106 (FITC 
conjugated, BD Biosciences), CD184 (FITC conjugated, BD Biosciences), CD73 (PE 
conjugated, BD Biosciences), CD105 (PE conjugated, BD Biosciences), CD29 (PE 
conjugated, BD Biosciences), CD166 (PE coniugated, Beckman Coulter), CD271 (PE 
conjugated, BD Biosciences), CD117 (PE coniugated, Beckman Coulter), CD14 (PE 
coniugated, Beckman Coulter), CD45 (ECD coniugated, Beckman Coulter), HLA-DR 
(PC7 coniugated, Beckman Coulter, Beckman Coulter  Inc. Brea, CA, USA 
http://www.beckmancoulter.com), CD19 (PE-Cy7 coniugated, Beckman Coulter), were 
used. Cells were labeled and incubated at R.T. for 15 minutes, washed and resuspended 
in 400 l Hank’s buffer before being analyzed on a FACS Aria III flow cytometer (BD 
Biosciences).  
 
3.1.6 hMSCs in vitro Differentiation Assay 
 
The ability of BM-MSCs and AT-MSCs to differentiate into adipocytes and osteoblasts 
was assayed both in hypoxia and normoxia as following described. 
 
- Adipogenesis differentiation: QUALITATIVE assay 
Once cells had reached confluence, adipogenic differentiation was induced by three 
cycles of 72 hours/each in a adipogenic induction medium (dexamethasone, insulin, 
indomethacin, 3-isobutyl-1-methyl- Xanthine, pen/strep, L-glutamine in MSCs growth 
medium) (Lonza, Walkersville, MD, USA, http://www.lonza.com). Following each 
round of induction, cells were maintained in a adipogenic maintenance medium for 
other 72 hours (high glucose-DMEM plus insulin) (Lonza). After final induction, 
hMSCs were grown for others 3 days into maintenance medium before fixing. cells in 
10% formalin for 15 minutes. Differentiated cells were identified by Oil Red O (Sigma-
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Aldrich, St. Louis, USA; http://www.sigmaaldrich.com), stain for lipid vacuoles. Plates 
were washed three times with dH2O to reduce non-specific staining. 
 
- Adipogenesis differentiation: QUANTITATIVE assay 
Quantitative analysis of Oil Red O staining can be performed by determining OD520 
(Optical Density) values of a set of known Oil Red O concentrations to obtain a 
calibration curve and then comparing these values to those obtained from the unknown 
sample. After evaluation of lipid vacuoles by qualitative differentiation analysis, Oil 
Red O lipid droplets stained were eluted by adding 100% isopropanol and incubated for 
at least 10 minutes. Solution obtained were measured at 520 nm using 
spectrophotometric techniques (Lambda 20 Spectrophotometer, Perkin Elmer, Milano, 
Italy; http://www.perkinelmer.com). 
Calibration curve was calculated using standard samples starting from an Oil Red O 
working solution properly diluted with dH20 to obtain serial dilutions. Blank control 
was 100% isopropanol. 
 
- Osteogenesis differentiation assay: QUALITATIVE assay 
The same rounds of induction and maintenance used for adipogenesis assay were 
performed. Osteogenic activation has required the presence of β glycerol-phosphate, 
ascorbic acid, dexamethasone, pen/strep, L-glutamine in MSCs growth medium 
(Lonza). Cells were fixed in 4% Para-formaldehyde for 5 minutes and differentiated 
cells were identified by Alizarin Red S (Sigma-Aldrich), stain for deposition of a 
calcium-rich mineralized elements. Cultures were rinsed two or three times with dH2O 
to reduce non-specific staining.  
 
- Osteogenesis differentiation assay: QUANTITATIVE assay 
Quantitative analysis of Alizarin Red Staining can be performed by determining OD405 
values of a set of known Alizarin Red concentrations to obtain a calibration curve and 
then comparing these values to those obtained from the unknown sample. After 
evaluation of deposition of a calcium-rich mineralized elements by qualitative 
differentiation analysis, 800 µL 10% Acetic Acid to each well of a six well plate 
(diameter: 35mm) were added and incubated for 30 minutes shaking. Monolayer was 
detached using a cell scraper and transferred in a 1.5 mL microcentrifuge tube, vortexed 
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and incubated at 85°C for 10 minutes and then in ice for 5 minutes. After incubation in 
ice, sample was centrifuged at 20,000 rpm for 15 minutes. The pH of the sample 
solution was neutralized by adding 10% Ammonium hydroxide and the OD was 
measured at 405 nm using spectrophotometric techniques. 
Calibration curve was calculated using standard samples starting from a solution 10X 
Alizarin Red properly diluted with dH20 to obtain serial dilutions.  
 
3.1.7 hMSCs Growth Curves 
 
After trypsinization, 2×10
4
 hBM-MSCs and AT-MSCs were seeded in a 12-well plate in 
1mL DMEM 20%FBS medium and cultured both in hypoxia and normoxia. Viable cells 
(trypan blue-excluding) were counted after 24, 48 and 72 hours on a Burker counting 
chamber.  
 
3.1.8 Co-colture assay 
 
To test the modulation of hGBM10 and hGBM13 cells markers expression under effect 
of hBM-MSCs, co-colture assays were performed at the same time both in normoxia 
and hypoxia.  
hBM-MSCs were seeded and grown as monolayer in DMEM 20% FBS medium under 
normoxic conditions. Before adding to the hMSCs monolayer, Hutu cells, grown at 2% 
or 21% O2, were properly labeled with PKH26 (PE conjugated, Sigma-Aldrich) or 
PKH67 (FITC conjugated, Sigma-Aldrich), two membrane dyes, at the final 
concentration of 2×10
-6 
M PKH-dye per 1×10
-7
cell/mL as recommended by Fluorescent 
Cell Linker Kit manufacturer’s instructions (Sigma). Co-coltures were incubated at 
37°C under hypoxic and normoxic conditions. After 7 days, cells were detached, 
resuspended in flow cytometry buffer (as described above) and labeled following the 
StemFlow Human Neural Lineage Analysis Kit manufacturer’s instructions (BD 
Biosciences). Briefly, samples were first labeled with CD-133/2-PE (MACS, Miltenyi 
Biotec, Bergisch Gladbach, Germany, http://www.miltenyibiotec.com) and CD44 
(Alexa700 coniugated, BD Biosciences), two surface markers, incubated at R.T. for 20 
minutes, washed and resuspended in 100µL fix-buffer, provided by the kit. After 15 
minutes incubation at R.T., cells were washed, pelleted and resuspended in 100µL 
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perm-buffer before adding the following markers: Nestin (Alexa Fluor 647 mouse anti-
Nestin), Sox-2 (PerCP-Cy 5.5 mouse anti-Sox2), βIII-tubulin (Alexa Fluor 488 mouse 
anti-βIII-tubulin), and GFAP (Alexa Fluor 647 mouse anti-GFAP). Samples were 
incubated at R.T. for 20 minutes, washed, resuspended in 400µL flow cytometry-buffer 
and analyzed on a FACS Aria III flow cytometer. 
 
3.1.9 hMSCs “in vitro” Migration Assay 
 
The tropism of BM-MSCs and AT-MSCs was valuated toward Hutu cells, growth 
factors and Hutu cells pre-treated with BMP2 and WNT3a biological agents, grown 
alternatively in hypoxia and normoxia, by an “in vitro” migration assay. Migratory 
properties of BM-MSCs and AT-MSCs towards Hutu pre-differentiated cells were 
performed treating tumor cells with BMP2 at the concentration of 20 ng/ml for five 
days or with the Wnt3a factor at 30 ng/ml concentration at for 7 days, before loading 
hMSCs on Transwell. Tumor cells were seeded in 12-well plates at a density of 4×10
4 
cells/well in 1mL DMEM-F12 medium in the lower well of a tissue culture Transwell 
plate (BD Biosciences). hMSCs, pre-labeled with DiI (Invitrogen), a lipophilic viable 
cell tracer, were plated in the upper well of Transwell plate at a density of 5×10
4
 cell per 
Transwell. Hutu cells and hMSCs were co-incubated for 7 days and then the number of 
hMSCs passed through the Transwell and therefore migrated toward Hutu cells and/or 
growth factors pre-treated cells into 180 seconds were counted by flow cytometer . The 
experiments were done in triplicate. 
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3.2 MATERIALS AND METHODS 
Part II 
 
3.2.1 Isolation and Expansion of GSCs 
  
In the second part of this study Human GSCs cultures: GBM2, GBM3, GBM4, and 
GBM5 of primary GBM surgical specimens were described. GBM specimens were 
obtained during surgical procedures of tumor removal previous a patient informed 
consent.  
 
3.2.2 Tissue Dissociation   
 
GSCs have been kindly provided by the Department of Molecular Medicine (Dr. 
Sgubin, Prof. Palù`) and cultured in neural stem cell media, as described in literature 
(Sgubin et al., 2012) (Kanai et al., 2012) (Wakimoto et al., 2009). 
 
3.2.3 Cell Cultures  
 
 GSCs were cultured as spheres in EF20 medium: Neurobasal Medium (GIBCO) 
supplemented with 3 mmol/l L-glutamine (Mediatech, Manassas,VA, 
http://www.cellgro.com), 1X B27 supplement (Life Technologies), 0.5XN2 
supplement (Life Technologies), 2 µg/ml heparin (Sigma-Aldrich), 20 ng/ml 
recombinant human EGF (R&D Systems Inc.), 20 ng/ml recombinant human 
FGF2 (Peprotech, Rocky Hill, NJ, http://www.peprotech.com), and 0.5X 
penicillin G-streptomycin sulfate-amphotericin B complex (Mediatech). The 
cultures were fed once a week with one-tenth volume of fresh medium. Cell 
passaging was performed by dissociation of spheres using NeuroCult chemical 
dissociation kit (StemCell) (Sgubin et al., 2012) (Kanai et al., 2012) (Wakimoto 
et al., 2009). 
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 VERO cells (African green monkey kidney) obtained from the Dept. of 
Microbiology and Virology of the University of Padova were grown and 
maintained in DMEM medium containing 10% FBS.  
 
3.2.4 Viruses 
 
 HSV1 wild type strain F is a prototype HSV-1 strain used in this study. 
 R3616, derived from HSV1 wild-type strain F, contains 1 kilobase-pair (1kbp) 
deletion in both copies of the γ134.5 gene (Chou et al., 1990). 
 
3.2.5 Virus titration plaque assay 
 
Vero cells were seeded in 6-well plates at a density of 20×10
4 
cells per well in 2mL 
DMEM 10% FBS medium and infected with serial dilutions of virus prepared in 0.7 ml 
of DMEM with 1%IFBS. After 2 hours virus inoculum was removed and cells were 
incubated in 1mL DMEM 1%IFBS supplemented with methylcellulose at 37°C until 
plaques were visible. Cells were fixed with methanol for Giemsa staining and plaques 
were counted to determine the viral titer as Plaque-Forming Unit (PFU)/mL (Kuroda et 
al., 2006).  
 
3.2.6 Cell Growth Curves 
 
After spheres dissociation, 2×10
4
 GBM2 and GBM4 cells were seeded in a 24-well 
plate in 500 µL EF20 medium and cultured. Viable cells (trypan blue-excluding) were 
counted on days 3, 6 and 9 on a Burker counting chamber.  
 
3.2.7 Virus Yield Assay 
 
GBM2 and GBM4 cells were single cell dissociated, seeded in 500 µL EF20 medium at 
the density of 2×10
4 
cells per well in 24-well plates and infected with HSV1 or R3616 at 
Multiplicity Of Infection (MOI) of 0.2 and 1.5 respectively. The cells were harvested 
with supernatant at 12, 24, 48 and 72 hours after infection and processed with three 
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freeze/thaw cycles and sonication. The titers of the viruses in the lysates were 
determined by plaque assay on Vero cells (Kuroda et al., 2006).  
For BM-MSCs viral yield assay, cells were seeded at the same density in 500 µL 
DMEM 20% FBS medium and monolayers were scraped into the medium to collect 
supernatants at previously indicated time points.  
 
3.2.8 Cell Killing Assay 
 
Single-cell suspensions of GSCs or BM-MSCs were seeded in 24-well plates at a 
density of 2×10
4 
cells per well and infected with HSV1 and R3616 at MOI of 0.2 and 
0.5 respectively. The cells were harvested at days 3, 6 and 9 and dissociated with 
0.25%/0.1% Trypsin/EDTA (GIBCO), and viable (trypan blue-excluding) cells were 
counted on a Burker counting chamber. 
 
3.2.9 Flow cytometry analysis 
 
Analysis of GBM2, GBM3, GBM4 and GBM5 phenotype was performed by using the 
Stemflow Neural Cell Lineage Kit following the manufacturer’s instructions previously 
described. 
Moreover for surface marker analysis, antibodies against human CD133 (clone 
AC133/2-PE, Miltenyi), CD90 (FITC conjugated, BioLegend), CD44 (FITC 
conjugated, BD Biosciences), CD24 (PC5 conjugated, Immunotech a.s., Praha, Czech 
Republic, http://www. immunotech.cz), CD105, CD29, and CD56 (all of them PE 
conjugated, BD Biosciences) were also been tested. 
 
3.2.10 BM-MSCs “in vitro” Migration Assay toward GSCs 
 
The BM-MSCs tropism towards GBM2 and GBM4 cells, toward the growth factors 
conditioned medium and GBM2 and GBM4 cells pre-treated with BMP2 was tested by 
“in vitro” migration assay under normoxic conditions using the same protocol 
previously described. GSCs were seeded in 12-well plates at a density of 4×10
4 
cells/ 
well in 1mL EF20 medium in the lower well of a tissue culture Transwell plate. To 
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induce differentiation, GBM cells were supplemented with BMP2 at the final 
concentration of 50ng/mL/day for 7 days before loading hMSCs on Transwell. 
To investigate BM-MSCs tropism toward GSCs previously HSV1 or R3616 infected, 
GBM2 and GBM4 cells were seeded at the same density, infected with HSV1 at MOI of 
0.1 and R3616 virus at MOI of 0.25. Prelabeled DiI-BM-MSCs were loaded 
respectively after 48 and 72 hours infection, according to the viral replication. 
Migratory properties were evaluated after 7 days of incubation using the same protocol 
above described. 
 
3.2.11 BMP2 and R3616 virus Combination Treatment Assay 
 
To investigate whether the infection of R3616 virus and the treatment with BMP2 could 
exert a combination effect in induce GSCs differentiation, GBM2 and GBM4 cells were 
seeded at a density of 6×10
4 
cells in 3 mL EF20 medium and infected with R3616 at 
MOI of 0.1. To induce differentiation, GBM cells were supplemented with BMP2 at the 
final concentration of 50ng/mL/day for 7 days before analyzing the expression of the 
Nestin, Sox2, βIII-tubulin and GFAP markers included by the Stemflow Neural Cell 
Lineage Kit using flow cytometric techniques. A mock control, GBM cells infected 
with R3616 or treated with BMP2 alone were also included.   
 
3.2.12 Western Blots 
 
Following proper treatment, cells were washed with 1X PBS, resuspended in RIPA 
buffer (Sigma-Aldrich) with Protease Inhibitors (Sigma-Aldrich), lysed on ice for 30 
minutes, and centrifuged for 10 minutes to separate cell debris. Protein concentrations 
of each sample were determined using the Micro BCA Protein Assay Kit (Thermo 
Fisher Scientific Inc., Meridian Rd Rockford, IL, USA, http://www.piercenet.com). 
Twenty micrograms of proteins were separated on a 7.5%, 10% or 12% SDS-
polyacrylamide electrophoresis gel, transferred to a Whatman membrane (GE 
Healthcare), and incubated with primary antibodies overnight at 4°C under shacking. 
The next day, membranes were incubated with secondary peroxidase-conjugated 
antibodies for 1 hour at R.T. Proteins were visualized using the ECL Advanced Western 
blotting detection Kit (GE Healthcare) on Kodak BioMax light (Sigma-Aldrich). The 
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primary antibodies were used as following: 1:1000 rabbit anti-CD133 (clone AC133/2, 
Miltenyi); 1:5000 goat anti-Nestin (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, 
USA; http://www.scbt.com)); 1:1000 rabbit anti-Sox2 (Cell Signaling Technologies Inc. 
Danvers, MA, USA; www.cellsignaling.com); 1:500 mouse anti-GFAP (Sigma-
Aldrich); 1:1000 rabbit anti-Tuj1 (Covance, Princeton, NJ, USA; www.covance.com); 
1:1000 mouse Pi-Smad1/5/8 (S463/465; S463/465; S426/428; Cell Signaling); 1:300 
rabbit Smad1/5/8 (Santa Cruz Biotechnology); 1:5000 mouse β-actin (Sigma-Aldrich) 
and 1:1000 mouse anti-α-Tubulin (Sigma Aldrich). Secondary antibodies were 
peroxidase-labeled
 
1:2000 goat anti-rabbit IgG (Sigma Aldrich) or peroxidase-labeled
 
1:2000 goat anti-murine IgG (Sigma Aldrich).  
 
3.3 Statistical analysis 
 
Graphs and statistical analyses were prepared using Prism 5 (Graph Pad Software, Inc., 
San Diego, USA; http://www.graphpad.com) or Excel. Values are presented as mean ± 
standard error (SD). Statistical significance was measured by two-tailored unpaired t-
test or one-way ANOVA with post-hoc Newman-Keul’s test, *P < 0.05, **P < 0.01, 
***P < 0.001.  P values less than 0.05 were considered statistically significant. 
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4.1 RESULTS 
Part I 
The following reported data have been obtained from the collaboration between two 
Departments of the University of Padova: the Laboratory of Oncohematology 
(Department of Woman and Child, Supervisor: Prof. G. Basso, MD) where I worked 
with Dr. Persano, PhD as tutor and the Microbiology and Virology Laboratory 
(Department of Molecular Medicine, Supervisor: Prof. G. Palù, MD) where my tutor 
was Dr. D. Sgubin, MD.  
Results presented in the first part of the study report cell delivery experiments 
employing human Mesenchymal Stem Cells as delivery vehicles for therapeutic 
molecules for the treatment of GBM.  
Data described in Part II focus on viral therapy experiments for GBM in GSCs primary 
cultures. 
 
 
 
 4.1.1 Isolation of human Mesenchymal Stem Cells (hMSCs) and cell 
culture  
hMSCs were collected from remaining samples of clinical bone marrow (BM-MSCs) 
transplantation drawing from consenting healthy volunteer donors or were derived from 
adipose tissue of glioma patients biopsies (AT-MSCs). Both hMSCs were isolated as 
the adherent fraction of mononuclear part by DMEM medium containing 20% FBS and 
grown in normoxic (21% O2) or hypoxic conditions (2% O2). Indeed, it was important 
to verify whether hMSCs were able to efficiently grow at both O2 levels once they 
reached the perivascular or the hypoxic GBM niche after delivering.  
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In Figure 13. is reported in example images of BM-MSCs at 48 hours (Panel A.) and 15 
days (Panel B.) after plating and grown in normoxia. 
 
 
 
 
 
 
Figure 13. Characterization of isolated human Bone Marrow Mesenchymal Stem Cells 
(BM-MSCs). Cells were cultured from marrow after density fractionation and are shown at 
48 hours after plating (Panel A.) and at 15 days after plating (Panel B.).  
 
BM-MSCs as well as AT-MSCs retained the typical spindle shape, consistent with the 
mesenchymal morphology reported in literature (Zuk et al., 2002) (Pittenger et al., 
1999) and no significant morphological differences between BM-MSCs and AT-MSCs 
neither in normoxia (Figure 14.), nor in hypoxia atmosphere were observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Morphological characterization of BM-MSCs and human Adipose Tissue 
Mesenchymal Stem Cells (AT-MSCs) isolated in DMEM medium containing 20% FBS and 
grown under normoxic (21% O2) (Panel A. and Panel B. respectively) and hypoxic (2% O2) 
(Panel C. and Panel D. respectively) conditions.  
B 
A B 
C D 
     BM-MSCs                       AT-MSCs 
   21% O2 
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 4.1.2 Characterization of stem like characteristics in AT- and BM-MSCs 
The purity of the mesenchymal lineage of selected cells was assessed by a phenotypic 
characterization that was confirmed 15 days after isolation.  
To evaluate hMSCs immune-phenotype, fifteen different cell surface markers were 
tested using cytofluorimetric techniques: CD90, HLA-DR, CD44, CD73, CD105, 
CD29, CD166; CD106, CD184, CD271, CD117, CD19, CD14, CD45, and CD133. 
Representative histograms are shown in Figure 15..  
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Figure 15. Immunophenotypic characterization of cell surface markers tested on hMSCs 
using cytofluorimetric techniques. BM-MSCs (red lines) and AT-MSCs (blue lines). 
Expression levels of CD90 (Panel A.), CD44 (Panel B.), CD73 (Panel C.), CD105 (Panel 
D.), CD29 (Panel E.), CD166 (Panel F.), CD106 (Panel G.), CD184 (Panel H.), CD271 
(Panel I.), CD19 (Panel L.), CD45 (Panel M.) and CD133 (Panel N.) are shown. Flow 
cytometric analysis performed 15 days after isolation, confirmed that hMSCs retained the 
same surface molecules as those found on hMSCs from which they were derived. Grey 
lines represent unlabeled hMSCs.  
 
According to criteria recommended by the International Society for Cellular Therapy 
(ISCT), our BM-MSCs and AT-MSCs positively expressed CD105 (endoglin receptor), 
CD73 (surface enzyme ecto-5’-nucleotidase), CD44 (hyaluronic receptor), CD90 
(extracellular matrix protein), as well as the adhesion molecules CD29 (β1-integrin), 
CD166 (activated leukocyte cell adhesion molecule) and CD271.  
Conversely, they were negative for the most common hematopoietic surface antigens, 
such as: CD14, CD19, CD45 (Le Blanc et al., 2003; Pittenger et al., 1999) 
(Chamberlain et al., 2007). 
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Detailed percentages of each surface marker expression are reported in Table2. 
 
Antibody                 BM-MSCs              AT-MSCs 
CD90 98,5±0.46 90 ± 1.8 
HLA-DR 7.5 ±3.45 11 ± 4.1 
CD44 94.33±0.87 92 ± 0.6 
CD73 99.5± 0.06 91 ± 2.8 
CD105 99.2± 1.13 89 ± 1 
CD29 78.2± 37.50 99 ± 1.8 
CD166 99.1± 0.65 81,5 ± 5.7 
CD106 15.32 ± 2.6 13.4 ± 7.1 
CD184 6.23 ± 3.80 negative 
CD271 2.6 ±2.2 20 ± 2.8 
CD117 negative 8 ± 2.8 
CD19 negative negative 
CD14 negative negative 
CD45 negative negative 
CD133 1.33 ± 0.76 negative 
Table 2. Phenotypic characterization of BM- and AT-MSCs: comparison of percentage of 
cell surface markers expressed by the two hMSC sources. Data acquired using 
cytofluorimetric thecniques. Each value represents the average percentage of at least three 
different experiments. ± is standard deviation (SD). 
 
We tested several BM- and AT-derived MSCs lines and all our cell lineages displayed a 
stable phenotype. Flow cytometric analysis repeated 15 days after the first 
characterization, confirmed that hMSCs from both sources retained the same surface 
molecules as those found on hMSCs from which they were derived.  
BM-MSCs was expected to be negative for CD106 expression, since CD106 is a 
vascular cell adhesion molecule associated with hematopoiesis (Zuk et al., 2002) 
(Chamberlain et al., 2007); accordingly, we found a low expression of CD106 both in 
BM-MSCs (15.3%) and in AT-MSCs (13.4%). 
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We also found slightly positive expression of the Human leukocyte antigen Class II 
(HLA-DR) antigen (7.5% on BM-MSCs and 11% on AT-MSCs), expected to be 
negative in adult hMSCs (Le Blanc et al., 2003) .  
AT-MSCs demonstrated a positivity of 8% for the expression of CD117 (c-kit), marker 
associated to hematopoietic phenotype, thus expected to be negative, as retained in our 
BM-MSCs. 
In general BM-MSCs expressed higher levels of selected cell surface markers in 
comparison to AT-MSCs, that could be related to the tissue source. Only CD271 
expression was found higher in AT-MSCs than BM-MSCs, counting for 20% versus 
2.6%. 
Noteworthy, the study of CD133, a putative stem cell marker (Singh et al., 2004b), 
revealed that it was slightly expressed only in BM-MSCs, whilst it was totally absent in 
AT-MSCs, as reported in the last row of Figure 15.. A CD133-positive cell fraction was 
previously documented in hMSCs isolated from umbilical cord blood and in mobilized 
peripheral blood (Tondreau et al., 2005) (Doucette et al., 2011). 
 
 4.1.3 In vitro qualitative and quantitative differentiation of BM-MSCs 
and AT-MSCs under normoxic and hypoxic conditions 
Upon the identification of mesenchymal lineage based on morphological and 
phenotypical characteristics, the stem cell nature of the BM-MSCs and AT-MSCs was 
in vitro confirmed by measuring their capacity to differentiate into multiple cell lineage.  
Our BM-MSCs and AT-MSCs were tested for their ability to differentiate into 
adipocytes and osteoblasts when grown in appropriate conditioning media containing 
pro- adipogenic or pro-osteogenic factors. Since it is well reported that hypoxia 
increases stemness (Bar, 2011) (Heddleston et al., 2009), these properties were assessed 
both at 21% and 2% O2. Representative results are reported in Figure 16.. 
Adipogenesis (Figure 16. Panel A.) was detected through accumulation of lipid 
vacuoles within the cells and stained with Oil Red O. Cells adopted a round morphology 
and formed cytoplasmic droplets. Osteogenesis (Figure 16. Panel B.) was assessed by 
the mineralization of extracellular matrix and the accumulation of calcium depositions 
stained with Alizarin Red S dye. 
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Figure 16. hMSCs differentiation assay. hMSCs isolated from BM- or AT- were tested for 
their ability to differentiate into adipocytes (Panel A.) or osteoblasts (Panel B.) when 
cultured under properly conditions for adipogenesis and osteogenesis both at 2% and 21% 
O2. A negative control for both cell line was also included. Original magnification ×20. 
 
BM-MSCs and AT-MSCs untreated control cultures, which were grown in regular 
medium without adipogenic or osteogenic differentiation stimuli, did not exhibit 
adipocyte or osteoblasts formation neither after 21 days of cultivation (see negative 
controls in Figure 16. Panel A.), thus confirming that our hMSCs did not differentiate 
spontaneously during culture expansion. 
B. 
 
A. 
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From the different assay conditions required for efficient differentiation, it is 
conceivable how basal nutrients, cell density, growth factors and cytokines can have a 
crucial role on hMSCs differentiation. 
As shown in Figure 16., BM-MSCs displayed more proliferative properties and a 
higher in vitro ability to differentiate into adipocytes or osteoblasts compared to AT-
MSCs. In particular, this efficiency was found greatly increased at 2% O2. Adipogenic 
differentiation demonstrated how AT-MSCs produced fewer and smaller lipid 
intracellular vacuoles than BM-MSCs, especially under normoxic conditions, 
suggesting that adipocytes in BM-MSCs could form earlier than in AT-MSCs and could 
be more mature. It is possible that a longer culture period could be necessary for 
adipogenic differentiation of AT-MSCs. 
 
To further confirm these data, quantitative differentiation analysis of adipogenesis 
(Figure 17. Panel A.) and osteogenesis (Figure 17. Panel B.) based on 
spectrophotometric techniques were performed under normoxic and hypoxic conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Histograms resembling BM-MSCs (black bars) and AT-MSCs (grey bars) 
quantitative adipogenic (Panel A.) and osteogenic (Panel B.) differentiation at 21% O2 and 
2% O2 tension. After fixing and staining hMSCs with Oil Red O dye in the case of 
adipocytes or with Alizarin Red S dye for osteoblasts, the intensity of the dye was measured 
at 520 and 405 nm respectively using spectroscopic techniques. The Optical Density (O.D.) 
ratios reported are been normalized to non-differentiated proper hMSCs (negative control). 
* P < 0.05 (two-tailored unpaired t-test) between indicated bars. Panel A. It has been found 
significantly difference between BM- and AT-MSCs in normoxia and hypoxia (*P < 0.05) 
and between BM-MSCs grown at 21% and 2% O2 (*P < 0.05). Panel B. It has been found 
significantly difference between BM- and AT-MSCs in normoxia (**P < 0.01) and hypoxia 
(*P < 0.05) and between BM-MSCs grown at 21% and 2% O2 (*P < 0.05). 
A. 
 
B. 
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As shown in Figure 17., BM-MSCs exhibited a statistically significant difference in 
ability to quantitative differentiate into adyposites and osteoblasts both under normoxic 
and hypoxic conditions compared to the AT-MSCs (*P < 0.05) confirming qualitative 
data reported in Figure 16.. Accordingly, in BM-MSCs quantitative adipogenic and 
osteogenic differentiation efficiency was found statistically increased in hypoxia (**P < 
0.01).  
 4.1.4 Cell growth analyses 
To verify whether BM-MSCs exhibited a more proliferative potential per sè in 
comparison to AT-MSCs, cells were grown under hypoxic and normoxic conditions and 
counted after 24, 48 and 72 hours (Figure 18.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Growth kinetics of BM- and AT-MSCs under hypoxic (grey check and triangle 
respectively) and normoxic (white check and triangle respectively) conditions. *** P<0.001 
(One-way ANOVA) indicated pairs are significantly different at 72h between BM- and AT-
MSCs in hypoxia and normoxia. Error bars are standard deviations (SD). 
A statistically significant difference in proliferation rate under hypoxic as well as under 
normoxic conditions was found at 72h after seeding both in BM-MSCs and AT-MSCs 
(P<0.001). BM-MSCs grew faster compared to AT-MSCs both in hypoxia and in 
normoxia (P<0.001). Indeed, BM-MSCs expanded 1.5-fold than AT-MSCs both in 
hypoxic and normoxic conditions after 72 hours, confirming an increased proliferative 
activity compared to AT-MSCs.  
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 4.1.5 In vitro evaluation of migratory properties of BM-MSCs and AT-
MSCs toward GBM derived stem like cells under HYPOXIC conditions 
Before evaluating migratory properties of BM- and AT-MSCs towards GBM derived 
cells, we verified that the selected medium for GBM cell cultures in which hMSCs 
should grow along the time of migration assay, did not modify their immunophenotype. 
Thus, cells were seeded alternatively in DMEM 20% FBS and in DMEM-F12 
supplemented with BIT serum substitute and cultured for seven days before analyzing 
some of the most common mesenchymal surface markers using cytofluorimetric 
techniques. For this analysis performed in BM-MSCs following markers investigated: 
CD44, CD73, CD90, CD105, CD106 and CD166 (Figure 19.).  
 
 
 
 
 
Figure 19. Immunophenotypic characterization of CD44, CD73, CD90, CD105, CD106 
and CD166 cell surface markers tested on BM-MSCs grown in DMEM 20% FBS and 
DMEM-F12 BIT media seven days after seeding. Data acquired using cytofluorimetric 
techniques. Except for CD106, all other markers evaluated retained the same expression 
levels when grown in DMEM-F12 plus BIT. CD106 was found significantly increased 
when BM-MSCs were grown in DMEM-F12 medium plus BIT (*P < 0.05). Error bars are 
standard deviation (SD).  
 
Except CD106 that demonstrated to be significantly increased when BM-MSCs were 
grown in DMEM-F12 medium supplemented with a serum substitute (*P < 0.05), no 
significant variations in markers expression levels were observed, suggesting that BM-
MSCs retained a stable phenotype even when grown along seven days. 
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BMP2 and WNT3a have been described in literature as astro-glial (Piccirillo et al., 
2006) (Persano et al., 2013) and neuronal (Rampazzo et al., 2013) pro-differentiating 
factors respectively; therefore, we sought to preliminary test whether a BMP2 or 
WNT3a pro-differentiating treatment of GBM cells would increase hMSCs migratory 
properties. Additionally, with the final aim to employ genetically engineered hMSCs 
expressing therapeutic genes, as delivery vehicles for brain tumor therapy, we 
investigated whether BMP2 or WNT3a, as two potential suitable agents, would enhance 
hMSCs tropism when loaded at the same time of hMSCs.  
By immunohistological analyses we previously verified GBM cells differentiation upon 
BMP2 and WNT 3a supplementation. Cells were treated with a single 20ng/mL BMP2 
spike/die per five days or 30 ng/mL WNT3a spike/die per seven days. Repeated 
applications were needed due to the short half-life of both biological agents tested. 
BMP2 treated GBM-derived cells were stained with βIII-tubulin (red) and GFAP 
(green) according to the protocol described in recently published data (Persano et al., 
2012) (Rampazzo et al., 2013). As shown in Figure 20., Panel A. BMP2 pre-treatment 
induced a increment of βIII-tubulin and GFAP expression levels in GBM cells 
compared to the control not treated. Similar results were observed when GBM cells 
received WNT 3a treatment (Figure 20., Panel B.). 
 
 
 
 
 
 
 
 
A. 
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Figure 20. Images showing phenotypic analysis of GBM cells. In Panel A.: hGBM CTRL 
and hGBM cells BMP2 treated and stained for βIII-tubulin (red), GFAP (green) and DAPI 
(blue) were analyzed. In Panel B.: hGBM CTRL and hGBM cells WNT3a treated and 
stained for βIII-tubulin (red), Nestin (green) and DAPI (blue) were analyzed. 10X 
Magnification.  
 
Hypoxia has been identified to play a critical role in promoting tropism of hMSCs 
toward GBM cells (Rochefort et al., 2006). Moreover, in order to assess whether 
cytokines released the GBM and other soluble factors, such as BMP2, as astro-glial pro-
differentiating agent, or WNT3a, as neuronal pro-differentiating molecule or whether 
oxygen levels could influence the hMSCs inherent tropism toward GBM cells, in vitro 
migration assays were performed under hypoxic conditions.  
To identify hMSCs migrated towards GBM-derived cells, hMSCs were previously 
labeled using the viable cell Tracer CM-DiI; then plated in the top well of a Transwell 
plate and counted using cytofluorimetric techniques seven days after seeding. To study 
the possible oxygen level effects exhibited on hMSCs tropism toward GBM-derived 
stem like cells, hGBM cells previously grown in hypoxia, were exposed at 21% O2 for 
15 days before loading hMSCs. Moreover, hMSCs in vitro migration was evaluated 
toward the hGBM cells conditioned medium; hGBM cells alone and hGBM cells added 
of 20ng/mL BMP2 or 30 ng/mL WNT3a at the same moment of hMSCs loading to 
monitor whether BMP2 or WNT3a presence could modulate hMSCs migration. A 
negative control (medium culture alone) was also included.  
B. 
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In Figure 21. is shown the in vitro migration profile retained by BM-MSCs and AT-
MSCs toward GBM stem like cells, treated or not under hypoxic conditions.  
Cells migration was calculated as a ratio, so-called migration index, normalizing the 
number of MSCs passed into 180 seconds in each conditions with the number of 
hMSCs passed to medium alone. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Migratory properties of BM-MSCs (black bars) and AT-MSCs (grey bars) 
toward GBM derived stem like cells under hypoxic conditions. C.M.: hGBM cells 
Conditioned Medium, hGBM: hGBM cells alone, hGBM+BMP2 pre: hGBM cells pre-
differentiated with BMP2 treatment at the concentration of 20 ng/ml for 5 days, 
hGBM+BMP2 co: 20ng/ml BMP2 added to hGBM cells at the same moment of hMSCs, 
hGBM+Wnt3a pre: hGBM cells pre-differentiated with Wnt3a treatment at the 
concentration of 30 ng/ml for 7 days, hGBM+Wnt3a co: 30ng/ml Wnt3a added to 
hGBM cells at the same moment of hMSCs, hGBM 20% O2 pre: hGBM cells pre-
differentiated at 20% O2 treatment for 15 days. hGBM 20% O2 co: MI of hMSCs referred 
to hGBM cells pre-differentiated at 20% O2 in normoxia. Migration index was calculated 
normalizing the number of hMSCs passed into 180 seconds in each conditions with the 
number of hMSCs passed to medium alone. Error bars are standard deviations (SD).  *P < 
0.05, ***P < 0.001 (one-way ANOVA) between indicated pairs in BM-MSCs. It has been 
found significantly difference between hGBM+Wnt3a pre and hGBM+Wnt3a co and 
between hGBM+BMP2 pre and hGBM+BMP2 co. 
 
Our results suggest that under hypoxic conditions, BMP2- and WNT3a-differentiated 
GBM stem like cells dramatically enhanced the migratory properties of BM-MSCs 
when cells were pre-treated, likewise when biological agents were supplemented to 
GBM cells at the same moment of hMSCs loading.  
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AT-MSCs appeared much less sensitive to all biological agents screened displaying a 
weak and aspecific migratory ability compared to BM-MSCs. 
For this reason we selected BM-MSCs as suitable cell carrier for further analyses. 
 
To directly estimate how oxygen levels could modulate hMSCs migratory properties, 
hMSCs-DiI
+
 were simultaneously loaded on GBM cells cultured at 2% and 21% O2 and 
counted seven days after seeding. In Figure 22. is reported the migratory properties of 
BM-MSCs toward hGBM cells (i.e. hGBM13) grown in hypoxia and normoxia. The in 
vitro migration was evaluated toward the GBM cells conditioned medium; GBM cells 
alone, GBM cells BMP2 pre-treated at the concentration of 20 ng/mL/die for 5 days and 
GBM cells added of 20ng/mL BMP2 at the same moment of hMSCs loading.  
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Comparison of in vitro migratory properties of BM-MSCs toward hGBM 
derived cells (i.e. hGBM13) under normoxic (white bars) and hypoxic (black bars) 
conditions. Conditioned Medium: GBM cells Conditioned Medium, hGBM: hGBM cells 
alone, hGBM(BMP2 treated): GBM cells pre-differentiated with BMP2 treatment at the 
concentration of 20 ng/ml for 5 days, hGBM+BMP2: 20ng/ml BMP2 added to GBM 
cells at the same moment of hMSCs. Migration index was calculated normalizing the 
number of hMSCs passed into 180 seconds in each conditions with the number of hMSCs 
passed to medium alone. Error bars are standard deviations (SD). *P < 0.05, **P < 0.01 
(two-tailored unpaired t-test) between indicated pairs. hGBM was found significantly 
different in normoxia and hypoxia (**P < 0.01). hGBM(BMP2 treated) was found 
significantly different in hypoxia and normoxia (**P < 0.01). hGBM+BMP2 was found 
significantly different in normoxia and hypoxia (*P < 0.05). Under hypoxic conditions it 
has been found significant difference between hGBM and hGBM(BMP2 treated) (*P < 
0.05). 
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Results demonstrated that the inherent migratory properties of BM-MSCs toward GBM 
cells alone, GBM cells BMP2 pre-differentiated for 5 days or enriched with BMP2 at 
the moment of hMSCs loading were greatly increased in hypoxic conditions. Moreover, 
the significantly difference found between hGBM and hGBM (BMP2) treated 
confirmed the enhancer effect induced by hypoxia on hMSCs migration upon BMP2 
treated cells of hGBM specimens (i.e. hGBM13). Conversely, GBM cells grown in 
normoxia did not exert any significant modulation on hMSCs homing. 
 
Taken together all these findings suggest how hypoxia as well as the treatment with 
BMP2 as pro-differentiating agent for GBM stem like cells greatly enhance the 
migration properties of hMSCs. 
BM-MSCs, displaying a more proliferative and growing properties, a greater ability to 
differentiate into multiple cell lineage and a higher inherent tropism toward GBM stem 
like cells in normoxia as well as in hypoxia compared to AT-MSCs, were selected the 
for future analyses of our study. 
 
 4.1.6 Direct modulation of GBM stem cell markers by BM-MSCs 
To better understand the effects exerted by BM-MSCs once reached tumor bed, we 
analyzed the expression of the most common stemness markers, such as Nestin (neural 
stem cells), Sox2 (neural stem cells), CD133 and differentiation markers, such as, βIII-
tubulin (neuronal), CD44 (astrocytes, astrocyte precursors) and GFAP (filament 
astrocytes) after co-culture with BM-MSCs in normoxia and hypoxia conditions, thus 
resembling both peculiar GBM niches. The BM-MSCs immunophenotypic 
characterization previously assessed in different media confirmed us that hMSCs 
retained a stable phenotype. To directly estimate how oxygen levels could modulate co-
colture, BM-MSCs were simultaneously seeded with hGBM cells and cultured at 2% 
and 21% O2 for seven days until measuring markers expression on hGBM cells with 
cytofluorimetric techniques. To recognize GBM cells from BM-MSCs, hGBM cells 
were previously label with PKH-26 and PKH-67, two membrane staining and grown as 
monolayer. 
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Examples of BM-MSCs co-cultured with hGBM cells under normoxia (Panel A.) and 
hypoxia (Panel B.) are shown in Figure 23.. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Modulation of hGBM cells and differentiation markers under effect of BM-
MSCs in normoxia (Panel A.) and hypoxia (Panel B.). Bar graph reporting relative Nestin+, 
Sox-2+, CD133+, βIII-tubulin+, CD44+ and GFAP+ hGBM cells quantification according to 
the BD Stemflow Human Neural Lineage Analysis Kit’s instructions. *P < 0.05, ***P < 
0.001 between indicated pairs (two-tailored unpaired t-test). In Panel A. it has been found 
statistical decrease of Nestin levels (*P < 0.05) and statistical increase of CD44 (*P < 0.05) 
and GFAP (***P < 0.001) levels. In Panel B. it has been found statistical decrease of 
Nestin and Sox2, levels (*P < 0.05) and statistical increase of CD44 (*P < 0.05) expression 
when hGBM cells were co-cultured with BM-MSCs. Results represent the average of two 
different experiments performed in triplicate. Error bars are standard deviations (SD). 
 
 
 
BM-MSCs in co-culture with hGBM cells under normoxic conditions (Panel A.) 
induced a statistical decrease of Nestin levels (*P < 0.05) with a concomitant statistical 
increase of GFAP (***P < 0.001) levels, suggesting how the presence of hMSCs could 
contribute to a more differentiated commitment in hGBM cells. Under hypoxic 
A. 
 
B. 
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conditions, (Panel B.) co-colture mediated a statistical decrease of Nestin and Sox2 (*P 
< 0.05) levels as well as a statistical increase of CD44 (*P < 0.05) levels, three stemness 
markers. Notably, CD133 was found dimly expressed at 21% O2; whereas at 2% O2 its 
expression was found increased, even in co colture, supporting studies that report how 
hypoxia promotes the expansion of CD133
+
 population through the activation of HIFs 
(Soeda et al., 2009) (Seidel et al., 2010) 
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4. 2 RESULTS 
Part II 
 
 4.2.1 Isolation and characterization of GBM stem like cell cultures from 
human GBM specimens 
 
In the second part of this study primary GSCs were grown as spheres under the culture 
conditions designed for selective expansion of neural stem cells (Sgubin et al., 2012) 
(Kanai et al., 2012) (Wakimoto et al., 2009). Representative images of the two different 
cultures mainly employed in our studies, GBM2 and GBM4 are shown in Figure 24.  
 
 
 
 
 
 
 
Figure 24. Phase contrast microscopic images of GBM2 (Panel A.) and GBM4 (Panel B.) 
spheres cultured in the serum free medium supplemented with EGF and bFGF. 
Original magnification ×10. Scale bar, 200 μm. 
 
Cells were characterized for the following stemness expression markers: CD133, 
Nestin, Sox2 and CD44 using cyto-fluorimetric techniques.  
Representative results of four different cultures phenotipically investigated: GBM2 
(Panel A.), GBM3 (Panel B.), GBM4 (Panel C.) and GBM5 (Panel D.) are shown in 
Figure 25.. 
B. GBM4 A. GBM2 
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Figure 25. Phenotypic characterization of four different GSC cultures: GBM2 (Panel A.), 
GBM3 (Panel B.), GBM4 (Panel C.) and GBM5 (Panel D.). Percentage of some of the 
most common stemness markers expressed by GSCs after isolation is indicated. Data 
acquired using cyto fluorimetric techniques. Error bars are standard deviations (SD).  
 
 
Flow cytometric analysis revealed that the levels of expression markers varied 
significantly among cultures. For example, CD133 antigen, a putative brain tumor stem-
like cells marker (Singh et al., 2004b) (Uchida et al., 2000), was highly expressed only 
in GBM2 (Panel A.), where it retained an expression of 88.8%; whereas, the percentage 
B. A. 
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4.2 Results 
73 
 
of CD133 positive cells in GBM3 (Panel B.), GBM4 (Panel C.) and in GBM5 (Panel 
D.) was less than 1%.  
Nestin, marker for neural stem/progenitor cells (Uchida et al., 2000) (Tohyama et al., 
1992) (Dahlstrand et al., 1992), reported the highest expression levels in GBM4 and 
GBM5, with a percentage of around 95.9% and 32.5% respectively. Conversely, Nestin 
was weakly expressed in GBM2 and in GBM3, counting less than 1%. Sox2, another 
neural stem cells marker (Cai et al., 2002) (Hemmati et al., 2003), was found expressed 
in GBM2 with a percentage of 58.7%, in GBM4 Sox2
+
 cells were around 48%, and in 
GBM5 around 64%. Differently, Sox2 was weakly expressed in GBM3, counting for 
only a 0.1%.  
CD44 is a transmembrane cell-surface adhesion protein (Ponta et al., 2003) assumed to 
be expressed in brain tumor stem cells (Singh et al., 2004a; Singh et al., 2004b). It’s 
expression widely varied among the four tested cultures: the highest expression levels 
of CD44 were observed in GBM3, counting for 92.8%, followed by GBM4 with a 
percentage of 42.6% CD44
+
 cells; whereas in GBM2 and GBM5 only the 13.5% and 
3.4% respectively was found expressing CD44.  
Taken together these results highlight how GSCs, as primary cultures, may be 
phenotypically more heterogeneous in comparison to their commercially obtained 
counterpart.  
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 4.2.2 Glioma stem-like cells growth 
In order to assess GSCs growth curves, GBM2 (Panel A.) and GBM4 (Panel B.) 
growing assays were performed (Figure 26.). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Growth kinetics of GBM2 (Panel A.) and GBM4 (Panel B.) cells under 
normoxic conditions. *P < 0.05, **P < 0.01, ***P < 0.001 between indicated pairs (one-
way ANOVA). In Panel A. it has been found significantly difference between day 0 and 
day 3 (*P < 0.05), day 0 and day 6 (**P < 0.01), day 0 and day 9 (***P < 0.001); between 
day 3 and day 6 (**P < 0.01) and between day 3 and day 9 (***P < 0.001). In Panel B. it 
has been found significantly difference between day 0 and day 6 (***P < 0.001), day 0 and 
day 9 (***P < 0.001); between day 3 and day 6 (***P < 0.001), day 3 and day 9 (***P < 
0.001) and between day 6 and day 9 (**P < 0.01). Error bars are standard deviations (SD). 
 
GBM2 and GBM4 growth kinetics was monitored upon 9 days, cells were counted 
every three days.  
Both GSC cultures demonstrated to grow well when cultured in serum free medium 
supplemented with proper growth factors EGF and bFGF (details in 3.2.3 “Material and 
Methods” section), reporting a statistical increment among days. 
At day 3 after plating, GBM2 cells were found doubled and 5-fold increased at day 9. 
The mean viability of the GBM2 was slightly higher compared to GBM4, that retained 
1.7-fold increased at day 3 and around 4.5-fold at day 9. 
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 4.2.3 In vitro replication assay of wild type HSV1 and R3616 
 
Critical for the selection of potential viral candidates for brain tumor therapy is their 
ability to replicate in human GSCs. Hence, GBM2 and GBM4 cells were first infected 
with HSV1 wild type at MOI of 0.2 and it’s replication efficiency was then compared to 
the replication ability of R3616, γ34.5 deleted HSV1, employed for our investigation.  
Supernatants were collected at 12, 24, 48 and 72 hours post infection. Cells became 
round, lost their morphological features, and detached from the culture plate since 90 
minutes after inoculation with viral suspensions. 
HSV1 wild type displayed a statistical significant ability to replicate in both GSCs 
tested, retaining a slightly higher replication ability in GBM2 compared to GBM4 cells. 
Indeed, in GBM2 72 hours after infection HSV1 wt viral titer was estimated increased 
around 1.8-fold (6.6 pfu/mL, log scale) than input (3.6 pfu/mL, log scale) (***P < 
0.001); whereas, in GBM4 the increment was around 1.7 (6 pfu/mL, log scale) (***P < 
0.001).  
Representative results of HSV1 replication ability in GBM2 (Panel A.) and GBM4 
(Panel B.) are shown in Figure 27.. 
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Figure 27. Replication of wild type HSV1 in infected GBM2 (Panel A.) and GBM4 cells 
(Panel B.). Cells were infected at an MOI of 0.2 and virus titer was determined at indicated 
times (hours) after infection. HSV1 displayed significant viral replication ability in both 
GBM2 and GBM4 cells. HSV1 input was 4*103 pfu/mL (log scale). **P < 0.01; ***P < 
0.001 between indicated points (one-way ANOVA). 
In Panel A. time points at 12, 24, 48 and 72 hours after infection were found significantly 
different compared to the input (***P < 0.001). It has been found significant difference 
between 12 hours and 24, 48 and 72 hours after infection (***P < 0.001); between 24 
hours and 48 and 72 hours after infection (***P < 0.001); between 48 and 72 hours after 
infection (**P < 0.01). In Panel B. time points at 12, 48 and 72 hours after infection were 
found significantly different compared to the input (***P < 0.001). It has been found 
significant difference between 12 hours and 24, 48 and 72 hours after infection (***P < 
0.001); between 24 hours and 48 and 72 hours after infection (***P < 0.001); between 48 
and 72 hours after infection (***P < 0.001). Error bars are standard deviations (SD). 
 
R3616 was not able to efficiently replicate both in GBM2 and GBM4 cells, even at 
MOI of 1.5, with viral yields lower than input (3×10
4
 pfu/mL) over the 72-h time 
course. Results are shown in Figure 28.. 
 
 
 
 
 
 
 
 
 
B. GBM4 
A. GBM2 
4.2 Results 
77 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Replication of R3616 in GBM2 (Panel A.) and GBM4 (Panel B.). Cells were 
infected at MOI of 1.5. R3616 did not replicate both in GBM2 and GBM4 cells, with virus 
yields less than input (3×104 pfu/mL) over the 72-h time course. **P < 0.01 between 
indicated points (one-way ANOVA): in Panel A. time points at 12, 24 and 48 hours after 
infection were found significantly different compared to the input (**P < 0.01). In Panel B. 
time points at 12 and 48 hours after infection were found significantly different compared 
to the input (***P < 0.001). It has been found significant difference between 12 hours and 
24 hours after infection (**P < 0.01) and between 24 hours and 48 hours after infection 
(**P < 0.01). Error bars are standard deviations (SD). 
 
 
 
 4.2.4 In vitro cell killing ability of wild type HSV1 and R3616 
 
In order to assess wild type HSV1 cytotoxicity in GSCs, GBM2 and GBM4 were 
infected with an MOI of 0.2 and counted after 3, 6 and 9 days.  
Wild type HSV1 exhibited significant killing effect in both GSCs tested. We observed 
an almost complete eradication of neurosphere cultures at day 9 after infection. In 
particular, GBM2 reported a fraction affected (FA) of 0.81 at day 6 and 0.94 at day 9 
found statistically different compared to FA at day 3 (***P < 0.001). In GBM4 cells FA 
resulted 0.69, 6 days after infection (***P < 0.001) and 0.93 after 9 days (***P < 0.001) 
as shown in Figure 29..  
No differences in killing ability were observed between tested GSCs and their FA 
values at day 9 were comparable.  
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Figure 29. wtHSV1 killing ability in GBM2 (Panel A.) and GBM4 cells (Panel B.). 2×104 
cells were infected at an MOI of 0.2 and viable cells were counted after 3, 6 and 9 days. *P 
< 0.05, ***P < 0.001 between indicated pairs (one-way ANOVA). In Panel A. FA has been 
found significantly difference between day 3 and day 6, between day 3 and day 9 (***P < 
0.001) and between day 6 and day 9 (*P < 0.05). In Panel B. FA has been found 
significantly different between day 3 and day 6, between day 3 and day 9 and between day 6 
and day 9 (***P < 0.001). Error bars are standard deviations (SD). 
 
To verify whether R3616 was able to replicate in GCSs, GBM2 and GBM4 cells have 
been infected with R3616 at an MOI of 0.2 or 0.5. Results reported in Figure 30. show 
R3616 killing ability in GBM2 and GBM4 assessed at MOI of 0.5. 
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Figure 30. R3616 killing ability in GBM2 (Panel A.) and GBM4 (Panel B.) cells. 2×104 
cells were infected at an MOI of 0.5 and viable cells were counted after 3, 6 and 9 days. *P 
< 0.05, **P < 0.01, ***P < 0.001 between indicated pairs (one-way ANOVA): in Panel B. 
FA between day 3 and day 6 (**P < 0.01), between day 3 and day 9 (***P < 0.001) and 
between day 6 and day 9 (*P < 0.05) was found significantly different in GBM4 cells 
infected with R3616. Error bars are standard deviations (SD). 
 
 
R3616 exhibited a more efficient killing ability on GBM4 compare to GBM2 reporting 
a fraction affected of 0.65 in GBM4 at day 6 (**P < 0.01) and 0.78 at day 9 (***P < 
0.001). Conversely, the R3616 FA in GBM2 attained to 0.4 at day 6 and did not exceed 
0.5 at day 9 . 
Taken together these findings indicated that both viruses were able to kill GSCs, albeit 
with significant different potency.  
 
 
To examine the effect of the γ34.5 deletion on GSCs, we compared R3616 cytotoxicity 
to HSV1 killing efficiency. GBM2 cells were infected with R3616 at the same MOI of 
0.2 used for HSV1 wt and viable cells were counted at day 3, 6 and 9 after infection. 
Obtained data are shown in Figure 31.  
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Figure 31. Comparison between HSV1 wt (black bars) and R3616 (white bars) cytotoxicity 
in GBM2. 2×104 cells were infected at an MOI of 0.2 and viable GBM2 cells were counted 
after 3, 6 and 9 days. ***P < 0.001, **P < 0.01 between indicated pairs (two-tailored 
unpaired t-test): FA between GBM2 cells HSV1wt infected and GBM2 cells R3616 infected 
at day 6 (**P < 0.01), and day 9 was found significantly different (***P < 0.001). Error bars 
are standard deviations (SD). 
 
As might be expected, HSV1 wt demonstrated to be significantly more cytotoxic than 
R3616. Although HSV1 wt and R3616 exhibited only a marginal different cytotoxicity 
at day 3, reporting a FA of 0.34 and 0.37 respectively, wild type HSV1 was found very 
efficacious in killing GBM2 cells with a FA of 0.81 at day 6 and 0.94 after 9 days. 
Differently, R3616 killing ability was significantly less efficient compared to HSV1 wt 
reporting a FA of 0.41 at day 6 (**P < 0.01) and stabilized at 0.48 at day 9 (***P < 
0.001).  
 4.2.5 In vitro evaluation of BMP2 treatment in GSCs 
Following the published data in other GBM cell cultures (Piccirillo et al., 2006) 
(Persano et al., 2012) (Pistollato et al., 2009b), the BMP2 ability to promote astro-glial 
differentiation in GSCs has been tested. Dissociated spheres from GBM2 and GBM4 
were supplemented with a single 50ng/mL BMP2 spike/die per seven days before 
analyzing the expression of the most common stemness (i.e. CD133, Nestin, Sox-2), 
neuronal differentiation (i.e. βIII-tubulin) and astrocytic differentiation (i.e. GFAP) 
markers using flow cytometric techniques. Since GCSc are slow replicating cells, 
BMP2 treatment was prolonged for 7 days. Daily repeated BMP2 applications were 
needed due to its short half-life.  
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In Figure 32. the phenotypic effects mediated by BMP2 treatment in GBM2 (Panel A.) 
and GBM4 cells (Panel B.) are shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Modulation of expression markers in GBM2 (Panel A.) and GBM4 (Panel B.) 
cells alone (black bars) or pre-treated with BMP2 (white bars) supplemented at the 
concentration of 50ng/mL BMP2 spike/die upon seven days. Bar graphs report relative 
CD133+, Nestin+, Sox2+, GFAP+ and βIII-tubulin+ quantified according to the BD 
Stemflow Human Neural Lineage Analysis Kit’s instructions using flow-cytometric 
techniques. *P < 0.05, (two-tailored unpaired t-test) between indicated pairs. In Panel A. it 
has been found significantly difference in Sox2+ (*P < 0.05) and in βIII-tubulin+ (**P < 
0.01) between GBM2 and GBM2 -BMP2 treated cells. In Panel B. it has been found 
significantly difference in Nestin+, βIII-tubulin+ and in GFAP+ between GBM4 and GBM4 
-BMP2 treated cells (*P < 0.05). Results represent the average of two different experiments 
performed in triplicate. Error bars are standard deviations (SD). 
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Upon supplementation of BMP2 to GBM2 cells, a statistical reduction in Sox2 
expression (from around 58% in GBM2 alone to 44.5% in GBM2-BMP2 treated cells) 
with a concomitant up-regulation of βIII-tubulin+ (from around 38% in GBM2 alone to 
56,5% in GBM2-BMP2 treated cells), neuronal marker, was observed (*P < 0.05). 
Conversely, no appreciable variation in CD133 and Nestin expression levels was found. 
CD133 positive cells remained very high, counting 90.5% in GBM2 and 89.9% in 
GBM2-BMP2 treated. Similarly, the GFAP positive population seemed not to be 
affected by BMP2 treatment, ranging from 27% to 23.85% upon BMP2 
supplementation.  
 
Following to the BMP2 treatment in GBM4 cells, flow cytometric analysis reported 
significantly increased in both expression levels of βIII-tubulin and GFAP (*P < 0.05); 
with the positive population ranging from 34.5% to 50.35% for the neuronal marker 
βIII-tubulin; while GFAP+ was around 44% in GBM4 alone and 60.9% in GBM4 
BMP2-pretreated cells. 
These data suggest that BMP2 treatment in GBM4 induce an increment of both 
neuronal and astroglial differentiation markers with concomitant significant decrement 
of Nestin levels. Indeed, Nestin was the only stemness marker decreased after BMP2 
supplementation. CD133
+
 population remained weakly expressed. No statistical 
differences were found in Sox2
+
 cell population either. 
 
Taken together, all these findings confirm that GBM2 and GBM4 cells do not retain the 
same aptitude to pro-differentiating effect modulated by BMP2. Moreover, in our 
analysis, beside an inter-cultures variability, there is an intra-culture variability, that 
typically occurs in primary cell lines, suggesting a possible variation in stem markers 
expression. 
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 4.2.6 Evaluation of BMP2 treatment in GSCs by Western Blot analysis 
 
The effects mediated by BMP2 in GSCs were evaluated through Western Blot assays. 
In Figure 33. are reported, as example, the expression of the proteins investigated in 
GBM4 lysates. 
GSCs, grown in normoxia, were daily supplemented with medium alone or 50 ng/mL 
and 100 ng/mL BMP2 for seven days in order to tested whether BMP2 pro 
differentiation ability was modulated in a concentration dependent manner. 
Proteins controlled were Nestin and Sox2, as stemness markers; βIII- tubulin and GFAP 
as differentiation markers. Additionally, it has been also preliminary evaluated in 
GBM4 the expression of Pi-Smad 1/5/8, downstream proteins of BMP2 signaling 
pathway, known to be activated in the phosphorylated state at 21% O2, whereas, it has 
been reported that hypoxia can repress BMP signaling pathway via Smad 
phosphorylation (Pistollato et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Representative western blot analyses in GBM4. Whole cell protein extracts 
were isolated following 7 days of medium or 50 and 100 ng/mL BMP2 treatment and 
subjected to western blot analysis. Proteins investigated were: Nestin, Sox-2, βIII-tubulin, 
GFAP, Pi-Smad 1/5/8 and Total Smad. α-tubulin and β-actin were alternatively used as 
loading control.  
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In GBM4 cells, analyses reported a modest downregulation of Nestin and concomitant 
up regulation of βIII-tubulin in a BMP2 concentration dependent manner. A slightly 
increase in GFAP levels is also appreciable when GBM4 cells were treated with 100 
ng/mL BMP2. 
 
BMPs pathway activity in GSCs was monitored by expression of the Pi-Smad 1/5/8 
proteins. Our preliminary analyses performed in GBM4 revealed an expression of 
proteins in phosphorylated state even in the control, suggesting that these proteins were 
expressed at 21% O2. Following BMP2 treatment Pi-Smad 1/5/8 were up regulated in a 
BMP2 concentration dependent manner. 
Total-Smad proteins analysis indicated a homogenous expression among conditions. 
Pi Smad 1/5/8 expression at 21% O2 could be due to the presence of endogenously 
secreted BMPs; thus, BMP2 supplementation would increase Pi Smad 1/5/8 levels. 
Further analyses to understand how BMP2 signaling pathway on GSCs is regulated in 
normoxia needed to be investigated. 
 
 
 4.2.7 Evaluation of in vitro migratory properties of BM-MSCs toward 
GSCs in presence of BMP2 
Before evaluating migratory properties of BM-MSCs towards GSCs, we verified that 
the selected medium for GSC cultures in which BM-MSCs should grow along the time 
of migration assay, did not impair their immunophenotype. Thus, hMSCs were seeded 
alternatively in DMEM 20% FBS and in EF 20 serum free media and cultured for seven 
days before analyzing some of the most common mesenchymal surface markers using 
cytofluorimetric techniques. For this analysis performed in BM-MSCs following 
markers investigated: CD44, CD73, CD90, CD105, CD106 and CD166 (Figure 33.). 
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Figure 34. Immunophenotypic characterization of CD44, CD73, CD90, CD105, CD106 
and CD166 cell surface markers tested on BM-MSCs grown in DMEM 20% FBS and 
EF20 serum free media seven days after seeding. Data acquired using cytofluorimetric 
techniques. Except for CD106, all other markers evaluated retained the same expression 
levels when grown in DMEM 20% FBS or EF20 media. CD106 was found significantly 
increased when BM-MSCs were grown in EF20 serum free medium selected for GSC 
cultures (**P < 0.01). Error bars are standard deviation (SD).  
Except CD106 that demonstrated to be significantly increased when BM-MSCs were 
grown in EF20 serum free medium selected for GSC cultures (**P < 0.01), no 
significant variations in markers expression levels were observed, suggesting that BM-
MSCs retained a stable phenotype even when grown along seven days. 
In order to verify whether cytokines and chemokines released by GSCs were able to 
promote hMSCs inherent tumor homing, we performed in vitro migration assays 
employing GBM2 and GBM4 cells. Moreover, to understand whether GSCs pre-treated 
with biological soluble factors supposed to induce astro-glial differentiation, such as 
BMP2, might modulate BM-MSCs tropism, we supplemented GBM2 and GBM4 cells 
with BMP2 at the concentration of 50ng/mL/day for 7 days or we added 50ng/mL 
BMP2 one time at the same moment of BM-MSCs loading.  
The in vitro migration assay was performed at 21% O2. BM-MSCs migratory effect was 
evaluated using the same conditions already described for in vitro migration assays as 
reported in Results Part 1 (see section 4.1.5). After seven days of incubation BM-MSCs 
tropism was quantified by cyto-fluorimetric techniques.  
Cells migration was calculated as a ratio, so-called migration index, normalizing the 
number of MSCs passed into 180 seconds in each conditions with the number of BM-
MSCs passed to medium alone. 
In Figure 35. is reported the BM-MSCs tropism towards GBM2 (Panel A.) and GBM4 
(Panel B.). 
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Figure 35. Migratory properties of BM-MSCs toward GBM2 (Panel A.) and GBM4 (Panel 
B.) under normoxic conditions. Conditioned Medium: GBM Conditioned Medium, 
GBM2 and GBM4: GBM cells alone; GBM2 or GBM4 (BMP2 treated): GBM cells pre-
differentiated with BMP2 treatment at the concentration of 50 ng/ml for 7 days; GBM2 or 
GBM4+BMP2: 50ng/ml BMP2 added to GBM cells at the same moment of BM-MSCs, 
Migration index was calculated normalizing the number of BM-MSCs passed into 180 
seconds in each conditions with the number of BM-MSCs passed to medium alone. *P < 
0.05, ***P < 0.001 (one-way ANOVA) between indicated pairs in BM-MSCs. In Panel A. it 
has been found significantly difference between Conditioned Medium and GBM2; GBM2 
and GBM2 (BMP2 treated) and GBM2 and GBM2+BMP2 (*P < 0.05). In Panel B. it has 
been found significantly difference between Conditioned Medium and GBM4 (BMP2 
treated), Conditioned Medium and GBM4+BMP2 (***P < 0.001), GBM4 and GBM4 
(BMP2 treated) (***P < 0.001) and between GBM4 and GBM4+BMP2 (*P < 0.05). 
Results represent the average of two different experiments performed in triplicate. Error 
bars are standard deviations (SD).  
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Our findings indicated that BM-MSCs migration was statistically enhanced toward 
GBM4 cells pre-treated with BMP2 in comparison to medium supplied of GBM4 
released factors or GBM4 cells grown alone (***P < 0.001). Significantly statistical 
was found the migratory effect exerted by GBM4 enriched one time with BMP2 in 
comparison to GBM4 conditioned medium (***P < 0.001) or GBM4 cells alone (*P < 
0.05) as well. 
Differently, in GBM2 we found statistically significant the BM-MSCs migration 
towards cells grown alone compared to supplemented medium and to GBM2 cells plus 
BMP2 (*P < 0.05). Unlike of GBM4, BMP2 did not exert any effect on GBM2 cells 
neither when cells were exposed to treatment for 7 days. 
 
GBM4 confirmed to be more responsive to BMP2 pro differentiating treatment than 
GBM2 and taken together our data suggest that GSCs more responsive to BMP2 
treatment greatly enhanced the BM-MSCs inherent tropism.  
 
 4.2.8 Evaluation of in vitro migratory properties of BM-MSCs toward 
GSCs infected with HSV-1 wt or R3616 
To investigate BM-MSCs tropism toward GSCs infected with wild type HSV1 and 
R3616, GBM2 or GBM4 cells were seeded at day 0; infected with HSV1 at MOI of 0.1 
or with R3616 virus at MOI of 0.25. BM-MSCs-DiI
+
 were loaded respectively 48 and 
72 hours post infection, according to the viral replication. Migratory properties were 
evaluated after 7 days of incubation at 21% O2. 
 
In Figure 36. is shown the migratory assay of BM-MSCs toward GBM2 (Panel A.) and 
GBM4 (Panel B.) infected with HSV1 wt. 
 
 
 
 
 
 
4.2 Results 
88 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Migratory properties of BM-MSCs toward GBM2 (Panel A.) and GBM4 (Panel 
A.) in normoxic conditions. GBM2 or GBM4: GSCs alone, GBM2 or GBM4+HSV1 wt: 
GSCs infected with HSV1 wt at MOI 0.1. Two days after infection with HSV1, BM-MSCs-
DiI+ were added on the top well of a Transwell plate. After seven days the number of BM-
MSCs passed through the Transwell into 180 seconds was counted using cytofluorimetric 
techniques. *P < 0.05 (two-tailored unpaired t-test). GBM4 results represent the average of 
two different experiments performed in triplicate. Error bars are standard deviations (SD).  
 
 
 
Data obtained infecting GBM4 cells with HSV1 wt demonstrated to significantly 
increase the migration of BM-MSCs (*P < 0.05). Conversely, there was no significant 
differences in hMSCs tropism when GBM2 cells were infected with HSV1 wt. 
 
We next assessed the migration properties of BM-MSCs toward GBM2 and GBM4 
when GSCs were been previously infected with R3616 at MOI 0.25. Interestingly, BM-
MSCs exhibited a statistical enhanced efficiency in migratory properties when GBM4 
cells were infected with R3616 (***P < 0.001) increasing their inherent tropism of more 
than 3.5 fold. Likewise for GBM2 infected with HSV1 wt, no significant difference in 
BM-MSCs migration was seen even when cells were infected with R3616.  
 
In Figure 37. are reported the in vitro migration assay of BM-MSCs toward GBM2 and 
GBM4 cells infected with R3616. Assays were performed under normoxic conditions. 
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Figure 37. Migratory properties of BM-MSCs toward GBM2 (Panel A.) and GBM4 (Panel 
A.) in normoxic conditions. GBM2 or GBM4: GSCs alone, GBM2 or GBM4+R3616: 
GSCs infected with R3616 at MOI 0.25. Three days after infection, BM-MSCs-DiI+ were 
added on the top well of a Transwell plate. After seven days the number of BM-MSCs 
passed through the Transwell into 180 seconds was counted using cytofluorimetric 
techniques. ***P < 0.001 (two-tailored unpaired t-test). GBM4 results represent the average 
of two different experiments performed in triplicate. Error bars are standard deviations 
(SD).  
 
 
Together these data demonstrated how GBM4-infected cells significantly improve the 
inherent tumor tropism of BM-MSCs, especially when cells were infected with R3616. 
Conversely, no significative effect related to HSV1 or R3616-infection was able to 
modify MSCs migration ability towards GBM2 cells.  
 
 4.2.9 BMP2 and R3616 Combination treatment in GBM4 
We previously showed that BMP2 treatment in GBM4 cells significantly enhanced βIII-
tubulin
+
 and GFAP
+
 with concomitant decrement of Nestin
+
 expression levels. In vitro 
migratory assays demonstrated that GBM4 cells pre-treated with BMP2 were 
significantly more attractive for BM-MSCs increasing their inherent tumor tropism. 
Conversely, the same effect was not retained in GBM2 cells. Moreover, we observed a 
greatly enhanced migration ability of BM-MSCs toward GBM4 cells infected with 
R3616. Taking into account all these findings, we next analyzed whether the 
combination treatment of BMP2 and R3616 promoted a stronger differentiation in 
GBM4 cells.  
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Cells were first infected with R3616 at MOI 0.1, according to the viral replication, and 
then treated with BMP2 at the concentration of 50ng/mL/day for 7 days before 
analyzing the cell phonotype through cyto fluorimetric techniques. GBM4 cells grown 
alone, supplemented only with BMP2 or infected with R3616 were also evaluated. To 
better understand the effects mediated by the co-treatment, Nestin, as representative 
marker of stemness and the two differentiation markers, βIII-tubulin and GFAP, found 
increased in GBM4-BMP2 treated cells, were analyzed for each conditions.  
 
 
Representative results of are shown in Figure 38.  
 
 
 
 
 
 
 
 
 
 
Figure 38. BMP2 and R3616 combination treatment in GBM4. Analysis performed using 
cyto-fluorimetric techniques. Cells were infected with R3616 at MOI 0.1 and treated with 
BMP2 at the concentration of 50ng/mL/day for 7 days. GBM4 cells grown alone, GBM4 
cells supplemented only with BMP2 50ng/mL/day for 7 days and GBM4 cells infected 
with R3616 at MOI 0.1 were also evaluated.*P < 0.05, **P < 0.01, ***P < 0.001 (one-way 
ANOVA) between indicated pairs in GBM4 cells. It has been found significant difference 
in Nestin expression between GBM4 and GBM4-BMP2 treated; GBM4-BMP2 treated and 
GBM4+R3616; GBM4-BMP2 treated and GBM4+BMP2+R3616 (**P < 0.01); in βIII-
tubulin expression between GBM4 and GBM4-BMP2 treated, GBM4+R3616 (*P < 0.05) 
and GBM4+BMP2+R3616 (**P < 0.01); in GFAP expression between GBM4 and 
GBM4-BMP2 treated, GBM4+R3616 and GBM4+BMP2+R3616 (***P < 0.001); between 
GBM4+BMP2 and GBM4+R3616 and between GBM4+BMP2 and 
GBM4+BMP2+R3616 (*P < 0.05). Error bars are standard deviations (SD). 
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Analysis of the combined treatment confirmed an up regulation of βIII-tubulin and 
GFAP with a concomitant down regulation of Nestin expression when GBM4 cells 
were supplemented with BMP2. Conversely, the R3616 infection seems do not to 
modify Nestin expression levels, even when cells received BMP2/R3616 co-treatment.  
We also evaluated the effect of the combination treatment with BMP2 and R3616 in cell 
viability, analyzing the percentage of positive live cells in each condition tested by 
cytofluorimetric techniques. 
A statistical decrease in percentage of live cells was observed when GBM4 cells were 
infected with R3616 alone in co-treatment with BMP2 and R3616 in comparison to 
GBM4 cells grown alone or BMP2-treated. Conversely any significative variation in 
cell viability was found when cells were treated only with BMP2. 
 
Representative results are shown in Figure 39.. 
 
 
 
 
 
 
 
 
Figure 39. Percentage of GBM4 cell viability in BMP2 and R3616 combination treatment 
assay. Cell viability was monitored in GBM4 cells grown alone, GBM4 cells supplemented 
only with BMP2 50ng/mL/day for 7 days; GBM4 cells infected with R3616 at MOI 0.1 
and in GBM4 cells infected with R3616 and treated with BMP2. *P < 0.05, (one-way 
ANOVA) between indicated pairs. It has been found significantly difference between 
GBM4 and GBM4+R3616; GBM4 and GBM4+BMP2+R3616; between GBM4+BMP2 
and GBM4+R3616 and between GBM4+BMP2 and GBM4+BMP2+R3616 (*P < 0.05). 
Error bars are standard deviations (SD).  
 
 4.2.10 R3616 effect on BM-MSCs 
With the final aim to exploit hMSCs inherent tumor tropism to deliver oncolytic virus, 
we preliminary tested the R3616 ability to replicate in and to kill BM-MSCs 
comparison to wild type HSV1. A suitable carrier must retain inherent tropism for 
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GSCs, must support the viral replication and release viral particles that subsequently 
will infect targeted cells. 
 4.2.10.1 In vitro replication assay of wild type HSV1 and R3616 in BM-
MSCs 
 
We evaluated viral replication in BM-MSCs after HSV1 wt infection at MOI of 0.2 or 
at MOI 1.5 with R3616. 
Representative results of HSV1 wt (Panel A.) and R3616 (Panel B.) growth curves are 
shown in Figure 40.. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Replication curves of wild type HSV1 (Panel A.) and R3616 (Panel B.) in 
infected BM-MSCs. Cells were infected at an MOI of 0.2 with HSV1 or 1.5 with R3616. 
Virus titer was determined at indicated times (hours) after infection. HSV1 input was 4×103 
pfu/ml; R3616 input was 3×104 pfu/ml. HSV1 and R3616 displayed significant (***P < 
0.001) viral replication ability compared to the viral input (one-way ANOVA). In Panel A. 
It has been found significant difference between 12h and 24h; 12h and 48h, 12h and 72h 
(***P < 0.001); between 24h and 48h (*P < 0.05), 24h and 72h (**P < 0.01) and between 
48h and 72h (*P < 0.05). Error bars are standard deviations (SD).  
 
B. 
A. 
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HSV1 demonstrated significative statistical replication efficiency in BM-MSCs 
reporting a viral titer more than 1.75 fold increased (6.42 pfu/mL, log scale) (***P < 
0.001) at 72 hours after infection. 
 
Conversely, R3616 was not able to efficiently replicate in BM-MSCs retaining a viral 
yield lower than input (3×10
4
 pfu/ml) over the 72-h time course.  
Taken together these findings indicated that the deletion of γ34.5 in R3616 significantly 
attenuates the potency of R3616 in BM-MSCs. 
 
 4.2.10.2 In vitro cell killing ability of wild type HSV1 and R3616 in BM-
MSCs 
In order to assess wild type HSV1 and R3616 cytotoxicity, BM-MSCs were infected 
with an MOI of 0.2 and 0.5 respectively and counted at day 3, 6 and 9 after infection.  
Killing ability of HSV1 wt (Panel A.) and R3616 (Panel B.) retained by the two viruses 
are shown in Figure 41.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
    HSV1wt titer: 7×10
7
 pfu/mL 
    MOI 0.2 
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Figure 41. Killing ability of HSV1 wt (Panel A.) and R3616 (Panel B.) in BM-MSCs. 2×104 
cells were infected at an MOI of 0.2 with HSV1 or 0.5 with R3616 and viable cells were 
counted after 3, 6 and 9 days. *P < 0.05, **P < 0.01, ***P < 0.001 between indicated pairs 
(one-way ANOVA): In Panel A. FA between day 3 and day 6, between day 3 and day 9 
(***P < 0.001) and between day 6 and day 9 (*P < 0.05) was found significantly different. 
In Panel B. FA between day 3 and day 6 (**P < 0.01), between day 3 and day 9 (***P < 
0.001) and between day 6 and day 9 (**P < 0.01) was found significantly different. Error 
bars are standard deviations (SD). 
 
 
HSV1 wt demonstrated to be more cytotoxic than R3616 in BM-MSCs even if the cells 
were infected with R3616 using a MOI 2.5 fold higher. 
Wild type HSV1 exhibited a greatly significative killing ability on BM-MSCs reporting 
a fraction affected of 0.76 at day 6 and 0.93 after 9 days.  
R3616 demonstrated a significative killing ability on BM-MSCs with a FA of 0.6 at day 
6 and 0.75 at day 9.  
 
 
 
 
 
 
 
B. 
R3616 titer: 2×10
6
 pfu/mL 
MOI 0.5 
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5. DISCUSSION 
Glioblastoma Multiforme (GBM) is the most malignant primary brain tumor in 
adults (Wen and Kesari, 2008), displaying high heterogeneity, fast growth, vascular 
proliferation, diffuse infiltration into the brain parenchyma and necrosis areas (Wen and 
Kesari, 2008) (Rong et al., 2006). The prognosis remains still dismal, despite the current 
optimal multimodal therapy (Stupp et al., 2005; Stupp et al., 2009b) (Crocetti et al., 
2012).  
One hypothesis to explain the poor GBM outcome seem to be related to the existence of 
a population of Cancer Stem Cells (CSCs) (Galli et al., 2004) (Dirks, 2008), recently 
reported to be involved in tumor initiation and progression (Hemmati et al., 2003; 
Ignatova et al., 2002; Singh et al., 2003) in the GBM as well as in other tumors (Bonnet 
and Dick, 1997) (Al-Hajj et al., 2003) (Esposito et al., 2002) (Ricci-Vitiani et al., 2007). 
These so-called Glioma stem cells (GSCs) are described as a sub-population of 
undifferentiated tumor-cells with stem-like properties including self-renewal capability, 
multi-lineage differentiation and highly tumorigenic potential when transplanted in 
immune-deficient mice (Galli et al., 2004) (Crocetti et al., 2012; Visvader and 
Lindeman, 2008) (Dirks, 2008). GSCs have been reported to express stemness markers 
(i.e. CD133, Sox2 and Nestin) and to exhibit multipotency when placed in defined 
serum-free stem cell medium (Hemmati et al., 2003; Ignatova et al., 2002; Singh et al., 
2003). Notably, accumulating evidence suggested that GSCs are important in tumor 
recurrence and in resistance to radiotherapy and chemotherapy (Wang et al., 2009) 
(Alcantara Llaguno et al., 2009). 
A parameter we considered with particular attention in our study was the tumor 
microenvironment. Indeed, the biology of GBM is characterized by a continuous change 
in the microenvironment that greatly influences tumor growth and response to therapies 
(Bleau et al., 2008). In particular, hypoxia plays a pivotal role in normal homeostasis of 
stem cells likewise in the initiation, development and aggressiveness of gliomas by 
modulating GBM derived cells phenotype (Li et al., 2009) (Wong and Brem, 2008) 
(Azuma et al., 2003; Jogi et al., 2002) (Gillespie et al., 2007). Recently, our group 
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described a novel concentric model of the tumour stem cells niche indicating that the 
more immature cells are localized in the inner core and in the intermediate layer of the 
tumour mass (Pistollato et al., 2010a) (Persano et al., 2011), highlighting how GBM 
nature is strictly linked to hypoxia and its peculiar microenvironment. Therefore, 
targeting GSCs located in the GBM niches may be critical.  
In our study we focused on two different therapeutic approaches to selectively target 
GSCs. 
 
a.) By taking advantage of the well known ability of Mesenchymal Stem Cells 
(MSCs) to migrate towards tumor sites (Nakamizo et al., 2005) (Doucette et al., 
2011) (Sasportas et al., 2009), we in vitro investigated hMSCs migratory 
properties with the final aim to genetically engineer them in order to express 
therapeutic genes thus exploiting hMSCs as delivery vehicles for brain tumor 
therapy.  
 
b.) We used the neuroattenuated herpes simplex virus type 1 vector, R3616, as a 
tool to selectively kill GSCs, sparing normal neural cells (Martuza et al., 1991). 
 
c.) We sought to exploit hMSCs tropism to tumor sites as delivery vehicles for 
R3616, possibly combining both strategies. 
 
Our laboratory has already reported the role of BMPs in promoting astro-glial 
differentiation in GBM stem like cells (Piccirillo et al., 2006) (Pistollato et al., 2009a) 
(Pistollato et al., 2009b) (Persano et al., 2011). Additionally, it is known the 
involvement of signaling molecules, such as bone morphogenetic proteins (BMPs) as 
crucial mediators of stem cell self-renewal and cell fate determination, which appear 
instead disrupted in brain cancers (Dirks, 2008). Piccirillo et al. (Piccirillo et al., 2006) 
showed that BMP4 (and analogously BMP2) can modulate glial differentiation through 
increase in GFAP expression in GBM primary cultures; in particular in the brain tumor 
inducing population, thus indicating BMPs as potentially useful candidate molecules to 
promote differentiation of the tumor-initiating cells.  
With the final aim to further transduce hMSCs with a vector harboring therapeutic 
genes, such as BMP2, to be released once cells have reached GBM site, we sought to 
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unravel whether BMP2 had some effect on hMSCs inherent tropism towards GBM stem 
like cells. Alternatively, we also pre-treated GBM-derived cells with BMP2 to verify 
whether pre-differentiated GSCs, become more permissive to hMSCs migration. 
Primary GBM-derived cells employed in this study were grown and cultured 
alternatively in adhesion (Conti et al., 2005) (Sun et al., 2008) (Pistollato et al., 2011) or 
in neurosphere suspension conditions (Reynolds and Weiss, 1992; Reynolds and Weiss, 
1996). In particular, GSC cultures as spheres were characterized for some of the most 
common stemness markers, such as CD133, (Singh et al., 2004b) (Uchida et al., 2000), 
Nestin (Uchida et al., 2000) (Tohyama et al., 1992) (Dahlstrand et al., 1992), Sox2 (Cai 
et al., 2002) (Hemmati et al., 2003) and CD44 (Singh et al., 2004a; Singh et al., 2004b). 
According to literature (Dirks, 2008) (Galli et al., 2004) (Gursel et al., 2011), our results 
clearly demonstrated that primary GSC cultures employed, expressed stemness markers 
with variable percentages, thus resembling GBM samples heterogeneity. These results 
highlight once again how GSCs, as primary cultures, may be phenotypically more 
heterogeneous in comparison to the commercially obtained counterpart. For example, 
CD133 was not always found highly expressed. Accordingly, recent publications 
provided evidence that GSCs can exist in the CD133-negative population (Beier et al., 
2007) (Chen et al., 2012) (Ogden et al., 2008). 
 
Concerning hMSCs, preliminary studies focused on the choice for the best hMSC 
candidate, between bone marrow- (BM-MSCs) and adipose tissue (AT-MSCs) derived 
hMSCs, for cell delivery experiments. According to criteria recommended by the 
International Society for Cellular Therapy (ISCT), our BM-MSCs and AT-MSCs 
positively expressed CD105, CD73, CD44, CD90, CD29, CD166, CD271 and were 
dimly positive for CD106, expected to be negative (Zuk et al., 2002) (Chamberlain et 
al., 2007). Conversely, they were negative for the most common hematopoietic surface 
antigens, such as CD14, CD19, CD45 (Le Blanc et al., 2003; Pittenger et al., 1999) 
(Chamberlain et al., 2007). We also found slightly positive expression of the Human 
leukocyte antigen Class II (HLA-DR) antigen expected to be negative in adult hMSCs 
(Le Blanc et al., 2003). Except for CD117 and CD271 expression, BM-MSCs more 
positively expressed cell surface markers in comparison to AT-MSCs. Noteworthy, 
analysis of CD133 expression revealed that it was slightly expressed only in BM-MSCs, 
whilst it was totally absent in AT-MSCs, in agreement to CD133 expression reported in 
5. Discussion 
98 
 
MSCs isolated from peripheral and umbilical cord blood (Tondreau et al., 2005) 
(Doucette et al., 2011). 
Human stem cell-based therapy have already shown to be a promising therapeutic 
approach for brain cancer (Aboody et al., 2000) (Aboody et al., 2000) (Tyler et al., 
2009) (Yuan et al., 2006). hMSCs have been used as delivery vehicles for therapeutic 
molecules in human gliomas (Lamfers et al., 2009) (Pierdomenico et al., 2005) (Huang 
et al., 2010), exhibiting selective tropism and migrating significant distances to target 
gliomas (Nakamizo et al., 2005). Indeed tumor cells, and in particular GBM cells (Zhou 
et al., 2002), secrete cytokines and chemokines that enhance hMSCs migration. hMSCs 
can be readily harvested from a broad range of sources, including adipose tissue (Zuk et 
al., 2001) (Zuk et al., 2002) and bone marrow (Bruder et al., 1997). AT-MSCs and BM-
MSCs derived hMSCs have extensively evaluated over last years as both of them offer 
the most accessible source of hMSCs for use in research and clinical applications. 
Adipose tissue is less invasive and less expensive than bone marrow to obtain (Locke et 
al., 2011) (Yoo et al., 2009). Additionally, unmodified AT-MSCs remain free of 
oncogenic transformation, demonstrating more oncogenic resistance than BM-MSCs 
(Momin et al., 2010). 
We isolated AT-MSCs from brain adipose tissue of glioma-bearing patient with the 
final aim to employed the same cells as therapeutic delivery vehicles for the treatment 
of GBM, thus presumably minimizing patient morbidity during cell harvesting, as 
already documented by Momin (Momin et al., 2010).  
To mimic the peculiar GBM microenvironment and to compare the growing efficiency 
of the two different sources within, we cultured hMSCs both in normoxic, at 21% O2, 
and hypoxic, at 2% O2, conditions. Clearly, the use of MSCs for the treatment of 
gliomas requires a population of cells with a doubling time and proliferation rate rapid 
enough to allow timely expansion of autologous cells for clinical applications. Although 
BM- and AT-MSCs resulted immunophenotypically quite similar, AT-MSCs had a 
significantly shorter doubling time, expanding around 1.5-fold less than BM-MSCs in 
72 hours both in hypoxic and normoxic conditions. These data were in agreement with 
data published by Ikegame et al. (Ikegame et al., 2011). Moreover, as demonstrated by 
in vitro multilineage developmental potential into adipocytes or osteoblasts assays, BM-
MSCs exhibited an significative increased proliferative activity compared to AT-MSCs, 
especially under hypoxic conditions. Harvest efficiency for AT-MSCs and BM-MSCs 
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have been reported to partially depend also on donor age (Strem et al., 2005): the hMSC 
population has been shown to decrease substantially with age, casting further doubt on 
the use of autologous hMSCs as a therapeutic delivery vehicle in patient-bearing glioma 
(Kern et al., 2006) taking into account the elderly median age of GBM patients (Crocetti 
et al., 2012) (Wen and Kesari, 2008).  
Finally, Pendleton et al. (Pendleton et al., 2013) in a study comparing the in vitro 
efficacy and specificity of AT-MSCs and BM-MSCs glioma tropism demonstrated how 
both sources retained similar homing. Differently, our studies reported that AT-MSCs 
showed a less efficient and aspecific migration toward GBM cells compared to BM-
MSCs, both in normoxia and in hypoxia; thus confirming BM-MSCs as the most 
efficient candidate for cell delivery. For this reason, we decided to employ BM-MSCs 
for our next experiments.  
 
Beside in normoxia and hypoxia, hMSCs migratory properties were investigated in the 
presence or absence of BMP2, WNT3a or after GBM derived cells were pre-treated 
with the two pro- differentiation factors. Wnt3a ligand mediates neuronal differentiation 
and proliferation inhibition of GBM cells and this phenomenon is enhanced under 
hypoxic conditions (Rampazzo et al., 2013).  
Under hypoxic conditions, BM-MSCs demonstrated to migrate preferentially toward 
both BMP2 or WNT3a pre-treated GBM cells or either when BMP2 and WNT 3a have 
been added at the same time of BM-MSCs loading, thus suggesting that hMSCs 
migration could be preferential toward more differentiated cells, or either differentiated 
GSCs are more permissive to hMSC migration. Under normoxic conditions BMP2 
treated cells not always increased hMSCs tropism. The exposure of stem cells to 
hypoxia increased hMSCs migration rate (Campos et al., 2010). Accordingly, we 
observed a significant increased hMSCs migration towards GBM cells grown under 
hypoxic conditions compared to normoxia. Notably, migratory properties were found 
more increased when hMSCs were loaded with BMP2 or WNT3a and were found 
dramatically increased when GBM cells have been pre-differentiated with these agents. 
This could be explained by considering a positive combination effect exerted by 
hypoxia and BMP2/WNT3a pro-differentiating agents able to efficiently enhance the 
hMSCs. Our results suggest that BMP2 can greatly increase the mesenchymal tropism 
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towards GBM site, even at lowered O2 levels. Interestingly we observed a scale 
migration manner ranging from normoxia to hypoxia. 
Such effect could be explain considering that hypoxia may enhance hMSCs migratory 
properties by upregulating chemotactic cytokines and by activating other signaling 
pathways that could involve also hMSCs (Fehrer et al., 2007). Further experiments need 
to be performed in order to elucidate this issue, but targeting GSCs exploiting BM-
MSCs inherent homing, seems to be a promising approach to deliver therapeutic agents, 
such as BMP2 to the tumor site, especially in hypoxia. Noteworthy, GSCs expressing 
high levels of CD133 did not modulate BM-MSCs migration when pre-treated with 
BMP2; conversely, the most efficient migration was observed versus GBM cells alone. 
Such effect can be explained by hypothesizing that stemness could impair in some ways 
hMSCs migratory properties, although this hypothesis should be better confirmed 
before we could consider it as realistic.  
 
Another approach we pursued to selectively targeting GSCs was represented by 
oncolytic viruses. Genetically engineered viruses have been widely investigated due to 
their capacity to selectively replicate in and kill cancer cells, while sparing normal 
neural cells (Martuza et al., 1991). For our studies we tested the therapeutical effect of 
the R3616, deleted for both copies of gene γ34.5, important for the virus replication and 
neurovirulence. Indeed, HSV wt can cause life-threatening encephalitis; thus attenuation 
is a prerequisite for a oHSVs. R3616 has already been demonstrated to in vitro replicate 
in and kill different human glioma cells (Martuza et al., 1991) (Andreansky et al., 
1997). In order to evaluate such ability in GSCs selected for our study, we tested R3616 
replication properties and cytotoxicity in comparison to HSV1 wild type. Analogously 
to Wakimoto et al., (Wakimoto et al., 2009) we found that the deletions of γ34.5 
occurred in R3616 negatively affected viral replication and attenuated cell killing ability 
in comparison to HSV wt.  
BM-MSCs migratory properties towards GSCs previously infected with HSV1 wt and 
R3616 under normoxic conditions were also evaluated.  
Notably, when we infected GSCs with HSV1 wt and R3616, we found an increased in 
BM-MSCs migratory properties, In particular, R3616 infection consistent enhanced 
hMSCs tropism retaining a the migration index 3.5-fold higher compared to HSV1 wild 
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type. This could be related to the enhancing effect exerted by oHSVs on 
chemoattractant receptors expression (Willmon et al., 2009). 
Differently, GSCs with high CD133 levels alternatively infected with HSV1 wt and 
R3616 seemed to impair hMSCs migration. 
Our data show that hMSCs could contribute to GBM cells differentiation per se. This 
was observed by co-culturing BM-MSCs with GBM derived cells. Interestingly, we 
noted that under both normoxic and hypoxic conditions hMSCs increased the 
expression of GBM differentiation markers and decreased the stemness markers 
percentage. Differently from data reported McLean et al. in a similar study on ovarian 
carcinoma (McLean et al., 2011) and by Prockop et al. (Prockop et al., 2010) for 
hematopoietic stem cells, our data do not suggest that hMSCs promote a cancer stem 
cell supporting milieu. A new study of Schichor (Schichor et al., 2012) on the 
interactions between glioma cells and hMSCs grown in co-culture revealed fusion 
between the two different cell types, resulting as multinucleated cells. Conversely, other 
studies have reported an inhibitory effect of the mesenchymal stem cells on the growth 
of the tumor (Schichor et al., 2012). However, hMSCs direct effect on tumor cells could 
be different and, in some way opposite, depending on tumor type. 
 
Finally, we sought to employ BM-MSCs as delivery vehicle for R3616. Cell-mediated 
vector delivery has been widely explored over last years for GBM (Short et al., 1990) 
(Kramm et al., 1995) (Nakamizo et al., 2005) (Doucette et al., 2011). It is possible to 
deliver viral particles to distant parts of the tumor exploiting tumor-tropic migratory 
cells as oncolytic virus carriers. Thus, the viral particles within cells may be protected 
from the host immune system and reach tumor site without be neutralized before 
exerting any effect (Yamamoto and Curiel, 2010) (Herrlinger et al., 2000). An ideal 
carrier should maintain the inherent tropism for the tumor site even after loading with 
the oncolytic virus and would support high levels of viral replication with concomitant 
minimal collateral damage to itself .  
Unfortunately, our data indicated that R3616 was not able to efficiently replicate in 
BM-MSCs, while it retained an efficient killing ability. For this reason we excluded the 
potential use of BM-MSCs as delivery vehicle for R3616.  
In summary, in this study we sought to point out which was the most pursuable 
therapeutic approach to selectively target GBM derived cells, by analyzing between 
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virotherapy, employing R3616 and the hMSCs as delivery vehicles to be further 
genetically engineered to express oHSVs as well as pro-differentiating molecules such 
as BMP2. We found that BM-MSCs were not possible to use as useful delivery vehicle 
of R3616 due to the hindered replication. Nevertheless, hMSCs demonstrated to 
efficiently migrate towards tumor site both in normoxia and hypoxia. In particular, 
hypoxia was confirmed to increase hMSCs migratory properties toward tumor site, 
showing an enhancing effect in presence of pro-differentiating molecules. Beside 
hypoxia, our data suggest other two different components as hMSCs migration 
enhancers: the R3616 as well as the BMP2 pro-differentiation treatment.  
This is the reason why we aim to combine both methods and, upon GSCs infection with 
R3616 and treatment with BMP2, estimate how hMSCs tropism is enhanced. 
Preliminary data collected in normoxia have already indicated that combination 
treatment increase differentiation markers more than BMP2 treatment alone. BM-MSCs 
employed for our studies seem to contribute to a GBM cells differentiation per sè; 
therefore our further efforts will direct to evaluate whether the combining treatment can 
improve hMSCs migratory properties as well. 
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